The	O
tumour	B-protein
associated	I-protein
cell	I-protein
surface	I-protein
antigen	I-protein
A6H	B-protein
is	O
costimulatory	O
for	O
human	B-cell_type
CD4+	I-cell_type
but	I-cell_type
not	I-cell_type
CD8+	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

The	O
A6H	B-protein
monoclonal	I-protein
antibody	I-protein
(	O
mAb	O
)	O
recognizes	O
a	O
120	B-protein
,	I-protein
000-140	I-protein
,	I-protein
000	I-protein
MW	I-protein
antigen	I-protein
that	O
is	O
expressed	O
at	O
similar	O
densities	O
on	O
85-90	O
%	O
of	O
human	O
CD4+	B-cell_type
and	I-cell_type
CD8+	I-cell_type
T	I-cell_type
cells	I-cell_type
and	O
on	O
renal	O
cell	O
carcinomas	O
.	O

The	O
binding	O
of	O
the	O
A6H	B-protein
mAb	I-protein
induced	O
a	O
costimulatory	O
signal	O
in	O
anti-CD3	B-cell_line
activated	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O

In	O
the	O
present	O
report	O
,	O
we	O
show	O
that	O
A6H	B-protein
costimulated	O
cell	O
proliferation	O
and	O
cytokine	B-protein
production	O
in	O
purified	O
CD4+	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Unexpectedly	O
,	O
the	O
CD8+	B-cell_type
T-cell	I-cell_type
subpopulation	I-cell_type
failed	O
to	O
respond	O
.	O

CD4+	B-cell_type
T	I-cell_type
cells	I-cell_type
costimulated	O
with	O
the	O
A6H	B-protein
mAb	I-protein
upregulated	O
CD80	B-protein
,	O
CD86	B-protein
,	O
CD71	B-protein
,	O
interleukin-2	B-protein
(	I-protein
IL-2	I-protein
)	I-protein
R	I-protein
alpha	I-protein
,	O
IL-2R	B-protein
beta	I-protein
and	O
IL-2R	B-protein
gamma	I-protein
,	O
while	O
no	O
corresponding	O
up-regulation	O
of	O
these	O
cell	B-protein
surface	I-protein
molecules	I-protein
was	O
seen	O
in	O
CD8+	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

In	O
order	O
to	O
investigate	O
the	O
nature	O
of	O
the	O
A6H	B-protein
mAb	I-protein
costimulus	O
at	O
the	O
transcriptional	O
level	O
we	O
have	O
examined	O
induction	O
of	O
the	O
transcription	B-protein
factors	I-protein
OCT-1	B-protein
,	O
AP-1	B-protein
and	O
NF-kappa	B-protein
B	I-protein
which	O
are	O
known	O
to	O
be	O
transcriptional	B-protein
regulators	I-protein
of	O
several	O
cytokine	B-protein
and	O
cytokine	B-protein
receptor	O
genes	O
,	O
including	O
the	O
IL-2	B-DNA
and	I-DNA
IL-2R	I-DNA
genes	I-DNA
.	O

Co-ligation	O
of	O
the	O
A6H	B-protein
antigen	O
and	O
the	O
CD3	B-protein
complex	I-protein
induced	O
expression	O
of	O
the	O
transcription	B-protein
factor	I-protein
AP-1	B-protein
in	O
CD4+	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
whereas	O
no	O
increase	O
in	O
NF-kappa	B-protein
B	I-protein
and	O
octamer-binding	B-protein
(	I-protein
Oct	I-protein
)	I-protein
proteins	I-protein
was	O
seen	O
compared	O
to	O
T	B-cell_type
cells	I-cell_type
stimulated	O
with	O
anti-CD3	B-protein
alone	O
.	O

Furthermore	O
,	O
no	O
induction	O
of	O
AP-1	B-protein
was	O
seen	O
in	O
A6H	B-protein
costimulated	O
CD8+	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

These	O
results	O
suggests	O
that	O
both	O
proximal	O
steps	O
in	O
CD8+	O
T-cell	O
activation	O
as	O
well	O
as	O
the	O
later	O
phases	O
are	O
unresponsive	O
to	O
A6H	B-protein
ligation	O
.	O

Molecular	O
differences	O
of	O
the	O
A6H	B-protein
molecule	I-protein
or	O
distinct	O
regulation	O
of	O
the	O
A6H	B-protein
transduced	O
AP-1	B-protein
activation	O
pathway	O
may	O
exist	O
in	O
CD4+	B-cell_type
and	I-cell_type
CD8+	I-cell_type
T	I-cell_type
cell	I-cell_type
subpopulations	I-cell_type
.	O

Immunology	NULL
1997	NULL
90	NULL
236-243	NULL
The	NULL
tumour	NULL
associated	NULL
cell	NULL
surface	NULL
antigen	NULL
A6H	NULL
is	NULL
costimulatory	NULL
for	NULL
human	NULL
CD4	NULL
*	NULL
but	NULL
not	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
T.	NULL
LABUDA	NULL
,	NULL
*	NULL
E.	NULL
PARRA	NULL
,	NULL
*	NULL
G.	NULL
HEDLUND	NULL
,	NULL
*t	NULL
T.	NULL
KALLAND*®	NULL
&	NULL
M.	NULL
DOHLSTEN*t	NULL
*Department	NULL
of	NULL
Tumour	NULL
Immunology	NULL
,	NULL
The	NULL
Wallenberg	NULL
Laboratory	NULL
,	NULL
University	NULL
of	NULL
Lund	NULL
,	NULL
Sweden	NULL
,	NULL
and	NULL
{	NULL
Pharmacia	NULL
&	NULL
Upjohn	NULL
,	NULL
Inc.	NULL
,	NULL
Lund	NULL
,	NULL
Sweden	NULL
SUMMARY	NULL
The	NULL
A6H	NULL
monoclonal	NULL
antibody	NULL
(	NULL
mAb	NULL
)	NULL
recognizes	NULL
a	NULL
120	NULL
000-140	NULL
000	NULL
MW	NULL
antigen	NULL
that	NULL
is	NULL
expressed	NULL
at	NULL
similar	NULL
densities	NULL
on	NULL
85-90	NULL
%	NULL
of	NULL
human	NULL
CD4*	NULL
and	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
and	NULL
on	NULL
renal	NULL
cell	NULL
carcinomas	NULL
.	NULL

The	NULL
binding	NULL
of	NULL
the	NULL
A6H	NULL
mAb	NULL
induced	NULL
a	NULL
costimulatory	NULL
signal	NULL
in	NULL
anti-CD3	NULL
activated	NULL
T	NULL
cells	NULL
.	NULL

In	NULL
the	NULL
present	NULL
report	NULL
,	NULL
we	NULL
show	NULL
that	NULL
A6H	NULL
costimulated	NULL
cell	NULL
proliferation	NULL
and	NULL
cytokine	NULL
production	NULL
in	NULL
purified	NULL
CD4*	NULL
T	NULL
cells	NULL
Unexpectedly	NULL
,	NULL
the	NULL
CD8*	NULL
T-cell	NULL
subpopulation	NULL
failed	NULL
to	NULL
respond	NULL
.	NULL

CD4*	NULL
T	NULL
cells	NULL
costimulated	NULL
with	NULL
the	NULL
A6H	NULL
mAb	NULL
upregulated	NULL
CD80	NULL
,	NULL
CD86	NULL
,	NULL
CD71	NULL
,	NULL
interleukin-2	NULL
(	NULL
IL-2	NULL
)	NULL
R	NULL
«	NULL
,	NULL
IL-2RB	NULL
and	NULL
IL-2Ry	NULL
,	NULL
while	NULL
no	NULL
corresponding	NULL
up-regulation	NULL
of	NULL
these	NULL
cell	NULL
surface	NULL
molecules	NULL
was	NULL
seen	NULL
in	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
.	NULL

In	NULL
order	NULL
to	NULL
investigate	NULL
the	NULL
nature	NULL
of	NULL
the	NULL
A6H	NULL
mAb	NULL
costimulus	NULL
at	NULL
the	NULL
transcriptional	NULL
level	NULL
we	NULL
have	NULL
examined	NULL
induction	NULL
of	NULL
the	NULL
transcription	NULL
factors	NULL
OCT	NULL
-1	NULL
,	NULL
AP-1	NULL
and	NULL
NF-	NULL
«	NULL
xB	NULL
which	NULL
are	NULL
known	NULL
to	NULL
be	NULL
transcriptional	NULL
regulators	NULL
of	NULL
several	NULL
cytokine	NULL
and	NULL
cytokine	NULL
receptor	NULL
genes	NULL
,	NULL
including	NULL
the	NULL
IL-2	NULL
and	NULL
IL-2R	NULL
genes	NULL
.	NULL

Co-ligation	NULL
of	NULL
the	NULL
A6H	NULL
antigen	NULL
and	NULL
the	NULL
CD3	NULL
complex	NULL
induced	NULL
expression	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
AP-1	NULL
in	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
,	NULL
whereas	NULL
no	NULL
increase	NULL
in	NULL
NF-xB	NULL
and	NULL
octamer-binding	NULL
(	NULL
Oct	NULL
)	NULL
proteins	NULL
was	NULL
seen	NULL
compared	NULL
to	NULL
T	NULL
cells	NULL
stimulated	NULL
with	NULL
anti-CD3	NULL
alone	NULL
.	NULL

Furthermore	NULL
,	NULL
no	NULL
induction	NULL
of	NULL
AP-1	NULL
was	NULL
seen	NULL
in	NULL
A6H	NULL
costimulated	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
.	NULL

These	NULL
results	NULL
suggests	NULL
that	NULL
both	NULL
proximal	NULL
steps	NULL
in	NULL
CD	NULL
#	NULL
8	NULL
#	NULL
*	NULL
T-cell	NULL
activation	NULL
as	NULL
well	NULL
as	NULL
the	NULL
later	NULL
phases	NULL
are	NULL
unresponsive	NULL
to	NULL
A6H	NULL
ligation	NULL
.	NULL

Molecular	NULL
differences	NULL
of	NULL
the	NULL
A6H	NULL
molecule	NULL
or	NULL
distinct	NULL
regulation	NULL
of	NULL
the	NULL
A6H	NULL
transduced	NULL
AP-1	NULL
activation	NULL
pathway	NULL
may	NULL
exist	NULL
in	NULL
CD4*	NULL
and	NULL
CD8	NULL
*	NULL
T	NULL
cell	NULL
subpopulations	NULL
.	NULL

INTRODUCTION	NULL
Activation	NULL
of	NULL
T	NULL
cells	NULL
to	NULL
proliferation	NULL
and	NULL
cytokine	NULL
production	NULL
requires	NULL
at	NULL
least	NULL
two	NULL
signals	NULL
.	NULL

The	NULL
first	NULL
signal	NULL
is	NULL
delivered	NULL
to	NULL
the	NULL
T-cell	NULL
receptor	NULL
(	NULL
TCR	NULL
)	NULL
by	NULL
antigen	NULL
in	NULL
the	NULL
context	NULL
of	NULL
major	NULL
histocompatability	NULL
complex	NULL
(	NULL
MHC	NULL
)	NULL
while	NULL
the	NULL
second	NULL
signal	NULL
is	NULL
provided	NULL
by	NULL
costimulatory	NULL
receptor	NULL
ligand	NULL
interactions	NULL
.	NULL

'~	NULL
``	NULL
In	NULL
the	NULL
absence	NULL
of	NULL
proper	NULL
costimulatory	NULL
signals	NULL
engagement	NULL
of	NULL
the	NULL
TCR	NULL
leads	NULL
to	NULL
clonal	NULL
inactivation	NULL
,	NULL
or	NULL
anergy	NULL
of	NULL
the	NULL
T	NULL
cells	NULL
.	NULL
``	NULL

A	NULL
number	NULL
of	NULL
molecules	NULL
including	NULL
B7	NULL
,	NULL
intercellular	NULL
adhesion	NULL
molecule	NULL
(	NULL
ICAM	NULL
)	NULL
,	NULL
lymphocyte	NULL
function-associated	NULL
antigen-3	NULL
(	NULL
LFA-3	NULL
)	NULL
and	NULL
vascular	NULL
cell	NULL
adhesion	NULL
molecule	NULL
(	NULL
VCAM	NULL
)	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
provide	NULL
costimulation	NULL
to	NULL
T	NULL
cells	NULL
upon	NULL
ligation	NULL
of	NULL
their	NULL
corresponding	NULL
receptors	NULL
CD28	NULL
,	NULL
LFA-1	NULL
,	NULL
CD2	NULL
and	NULL
very	NULL
late	NULL
antigen-4	NULL
(	NULL
VLA-4	NULL
)	NULL
,	NULL
respectively	NULL
.	NULL
``	NULL

''	NULL
``	NULL
'	NULL
``	NULL
The	NULL
receptors	NULL
Received	NULL
3	NULL
September	NULL
1996	NULL
;	NULL
revised	NULL
10	NULL
October	NULL
1996	NULL
;	NULL
accepted	NULL
16	NULL
October	NULL
1996	NULL
.	NULL

Abbreviations	NULL
:	NULL
AP	NULL
,	NULL
activator	NULL
protein	NULL
;	NULL
FITC	NULL
,	NULL
fluorescein	NULL
isothiocy-anate	NULL
;	NULL
NF	NULL
,	NULL
nuclear	NULL
factor	NULL
;	NULL
PBL	NULL
,	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
;	NULL
PBS	NULL
,	NULL
phosphate-buffered	NULL
saline	NULL
;	NULL
PE	NULL
,	NULL
phycoerythrin	NULL
;	NULL
RCC	NULL
,	NULL
renal	NULL
cell	NULL
carci-noma	NULL
;	NULL
TNF	NULL
,	NULL
tumour	NULL
necrosis	NULL
factor	NULL
.	NULL

Correspondence	NULL
:	NULL
Dr	NULL
Mikael	NULL
Dohisten	NULL
,	NULL
Department	NULL
of	NULL
Tumour	NULL
Immunology	NULL
,	NULL
The	NULL
Wallenberg	NULL
Laboratory	NULL
,	NULL
University	NULL
of	NULL
Lund	NULL
,	NULL
Box	NULL
7031	NULL
,	NULL
$	NULL
-220	NULL
07	NULL
Lund	NULL
,	NULL
Sweden	NULL
.	NULL

LFA-1	NULL
,	NULL
CD2	NULL
and	NULL
VLA-4	NULL
are	NULL
expressed	NULL
,	NULL
at	NULL
variable	NULL
density	NULL
,	NULL
on	NULL
a	NULL
majority	NULL
of	NULL
T	NULL
cells	NULL
wheras	NULL
CD28	NULL
is	NULL
expressed	NULL
on	NULL
virtually	NULL
all	NULL
CD4*	NULL
and	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
.	NULL
``	NULL

We	NULL
have	NULL
recently	NULL
reported	NULL
the	NULL
existence	NULL
of	NULL
the	NULL
A6H	NULL
antigen	NULL
,	NULL
a	NULL
novel	NULL
costimulatory	NULL
molecule	NULL
co-expressed	NULL
on	NULL
T	NULL
cells	NULL
and	NULL
renal	NULL
cell	NULL
carcinomas	NULL
.	NULL

'*	NULL
``	NULL
``	NULL
The	NULL
AGH	NULL
monoclonal	NULL
antibody	NULL
(	NULL
mAb	NULL
)	NULL
detected	NULL
a	NULL
120000-140000	NULL
MW	NULL
molecule	NULL
expressed	NULL
at	NULL
equally	NULL
high	NULL
densities	NULL
on	NULL
88	NULL
%	NULL
of	NULL
CD4*	NULL
and	NULL
84	NULL
%	NULL
of	NULL
CD8*	NULL
T	NULL
cells	NULL
.	NULL
``	NULL

Engagement	NULL
of	NULL
the	NULL
A6H	NULL
antigen	NULL
induced	NULL
T-cell	NULL
proliferation	NULL
and	NULL
cytokine	NULL
production	NULL
in	NULL
CD3	NULL
triggered	NULL
human	NULL
T	NULL
cells	NULL
.	NULL

A6H	NULL
costimulation	NULL
was	NULL
clearly	NULL
distinct	NULL
from	NULL
the	NULL
profile	NULL
obtained	NULL
by	NULL
costimulation	NULL
through	NULL
CD28	NULL
.	NULL

Costimulation	NULL
with	NULL
A6H	NULL
resulted	NULL
in	NULL
delayed	NULL
activation	NULL
with	NULL
production	NULL
of	NULL
high	NULL
levels	NULL
of	NULL
interferon-y	NULL
(	NULL
IFN-y	NULL
)	NULL
,	NULL
tumour	NULL
necrosis	NULL
factor	NULL
(	NULL
TNF	NULL
)	NULL
and	NULL
moderate	NULL
amounts	NULL
of	NULL
IL-2	NULL
.	NULL
``	NULL

In	NULL
contrast	NULL
,	NULL
CD28	NULL
costimulation	NULL
supported	NULL
a	NULL
rapid	NULL
activation	NULL
and	NULL
super-induced	NULL
IL-2	NULL
production	NULL
.	NULL

In	NULL
the	NULL
present	NULL
study	NULL
we	NULL
have	NULL
investigated	NULL
the	NULL
role	NULL
of	NULL
A6H	NULL
costimulation	NULL
in	NULL
CD4*	NULL
and	NULL
CD8*	NULL
subsets	NULL
of	NULL
human	NULL
T	NULL
cells	NULL
.	NULL

A6H	NULL
mAb	NULL
induced	NULL
cytokine	NULL
production	NULL
and	NULL
up-regulation	NULL
of	NULL
IL-2R	NULL
«	NULL
,	NULL
#	NULL
and	NULL
y-chains	NULL
,	NULL
CD71	NULL
,	NULL
B7-1	NULL
and	NULL
B7-2	NULL
in	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
.	NULL

However	NULL
,	NULL
to	NULL
our	NULL
surprise	NULL
A6H	NULL
mAb	NULL
failed	NULL
to	NULL
costimulate	NULL
the	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
.	NULL

A	NULL
vital	NULL
checkpoint	NULL
for	NULL
the	NULL
control	NULL
of	NULL
T-cell	NULL
activation	NULL
versus	NULL
inactivation	NULL
involves	NULL
the	NULL
transcription	NULL
of	NULL
the	NULL
IL-2	NULL
gene	NULL
.	NULL
``	NULL

©1997	NULL
Blackwell	NULL
Science	NULL
Ltd	NULL
Costimulatory	NULL
effects	NULL
of	NULL
A6H	NULL
on	NULL
human	NULL
T	NULL
cells	NULL
237	NULL
Regulation	NULL
of	NULL
the	NULL
IL-2	NULL
enhancer/promoter	NULL
region	NULL
is	NULL
controlled	NULL
by	NULL
several	NULL
transcription	NULL
factors	NULL
including	NULL
octamer-binding	NULL
(	NULL
Oct	NULL
)	NULL
proteins	NULL
NF-AT	NULL
,	NULL
NF-xB	NULL
,	NULL
AP-1	NULL
and	NULL
the	NULL
CD28	NULL
responsive	NULL
complex	NULL
(	NULL
CD28RC	NULL
)	NULL
,	NULL
all	NULL
binding	NULL
to	NULL
distinct	NULL
elements	NULL
in	NULL
a	NULL
300	NULL
bp	NULL
region	NULL
5°	NULL
of	NULL
the	NULL
transcription	NULL
start	NULL
site	NULL
.	NULL
``	NULL

''	NULL
Among	NULL
these	NULL
transcription	NULL
factors	NULL
AP-1	NULL
and	NULL
NF-xB	NULL
seem	NULL
to	NULL
be	NULL
of	NULL
particular	NULL
relevance	NULL
since	NULL
they	NULL
are	NULL
involved	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
several	NULL
cytokine	NULL
genes	NULL
and	NULL
also	NULL
complex	NULL
with	NULL
other	NULL
transcription	NULL
factors	NULL
such	NULL
as	NULL
OCT	NULL
,	NULL
NF-AT	NULL
and	NULL
CD28RC	NULL
.	NULL

'*~	NULL
'	NULL
``	NULL
In	NULL
the	NULL
present	NULL
report	NULL
we	NULL
show	NULL
that	NULL
A6H	NULL
costimulation	NULL
of	NULL
CD4*	NULL
T	NULL
cells	NULL
induced	NULL
high	NULL
levels	NULL
of	NULL
AP-1	NULL
binding	NULL
protein	NULL
but	NULL
failed	NULL
to	NULL
upregulate	NULL
NF-xB	NULL
binding	NULL
proteins	NULL
.	NULL

The	NULL
results	NULL
suggest	NULL
that	NULL
the	NULL
A6H	NULL
antigen	NULL
represent	NULL
a	NULL
unique	NULL
pathway	NULL
for	NULL
selective	NULL
induction	NULL
of	NULL
AP-1	NULL
responding	NULL
cytokines	NULL
and	NULL
cytokine	NULL
receptor	NULL
genes	NULL
in	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Reagents	NULL
and	NULL
cell	NULL
lines	NULL
The	NULL
mAb	NULL
A6H	NULL
,	NULL
earlier	NULL
was	NULL
a	NULL
kind	NULL
gift	NULL
from	NULL
Dr	NULL
Robert	NULL
Vessella	NULL
,	NULL
University	NULL
of	NULL
Washington	NULL
,	NULL
Seattle	NULL
,	NULL
WA	NULL
.	NULL

Ficoll-Paque	NULL
and	NULL
Percoll	NULL
were	NULL
purchased	NULL
from	NULL
Pharmacia	NULL
Inc.	NULL
,	NULL
Uppsala	NULL
,	NULL
Sweden	NULL
.	NULL

The	NULL
mAb	NULL
Leu	NULL
2a-fluoroscein	NULL
isothiocyanate	NULL
(	NULL
FITC	NULL
)	NULL
(	NULL
anti-CD8	NULL
)	NULL
,	NULL
Leu	NULL
3a-FITC	NULL
(	NULL
anti-CD4	NULL
)	NULL
,	NULL
Leu	NULL
4-PE	NULL
(	NULL
anti-CD3	NULL
)	NULL
,	NULL
anti-IL-2R	NULL
«	NULL
-PE	NULL
(	NULL
anti-CD25	NULL
)	NULL
and	NULL
anti-CD71-FITC	NULL
were	NULL
purchased	NULL
from	NULL
Becton	NULL
Dickinson	NULL
Laboratories	NULL
,	NULL
Mountain	NULL
View	NULL
,	NULL
CA	NULL
.	NULL

The	NULL
mAb	NULL
UCH-TI-FITC	NULL
(	NULL
anti-CD3	NULL
)	NULL
,	NULL
and	NULL
FITC	NULL
rabbit	NULL
F	NULL
(	NULL
ab	NULL
)	NULL
;	NULL
anti-mouse	NULL
immunoglobulin	NULL
were	NULL
purchased	NULL
from	NULL
Dakopatts	NULL
,	NULL
Glostrup	NULL
,	NULL
Denmark	NULL
.	NULL

The	NULL
mAb	NULL
OKT-3	NULL
was	NULL
obtained	NULL
from	NULL
Ortho	NULL
Diagnostic	NULL
System	NULL
,	NULL
Raritan	NULL
,	NULL
NJ	NULL
.	NULL

The	NULL
mAb	NULL
anti-C215	NULL
(	NULL
reactive	NULL
with	NULL
a	NULL
human	NULL
colon	NULL
carcinoma	NULL
antigen	NULL
;	NULL
used	NULL
as	NULL
immunoglobulin	NULL
G	NULL
(	NULL
IgG	NULL
)	NULL
control	NULL
mAb	NULL
)	NULL
has	NULL
been	NULL
described	NULL
earlier	NULL
.	NULL

'*	NULL
The	NULL
mAb	NULL
anti-B70-phycoerythrin	NULL
(	NULL
PE	NULL
)	NULL
,	NULL
IL-2RG-PE	NULL
and	NULL
IL-2Ry-PE	NULL
were	NULL
purchased	NULL
from	NULL
PharMingen	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
.	NULL

The	NULL
mAb	NULL
anti-CD28	NULL
was	NULL
obtained	NULL
from	NULL
Immunotech	NULL
,	NULL
Westbrook	NULL
,	NULL
ME	NULL
,	NULL
and	NULL
the	NULL
mAb	NULL
anti	NULL
CD80-F	NULL
from	NULL
Ancell	NULL
,	NULL
Bayport	NULL
,	NULL
MN	NULL
.	NULL

The	NULL
CTLA-4	NULL
immunoglobulin	NULL
fusion	NULL
protein	NULL
``	NULL
was	NULL
a	NULL
generous	NULL
gift	NULL
from	NULL
Dr	NULL
Linsley	NULL
,	NULL
Bristol	NULL
Meyers	NULL
Squibb	NULL
,	NULL
Seattle	NULL
,	NULL
WA	NULL
,	NULL
and	NULL
the	NULL
CD33Fc	NULL
fusion	NULL
protein	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
Dr	NULL
Simmons	NULL
,	NULL
Oxford	NULL
,	NULL
UK	NULL
.	NULL

Dynabeads	NULL
coated	NULL
with	NULL
goat	NULL
anti-mouse	NULL
IgG	NULL
were	NULL
purchased	NULL
from	NULL
Dynal	NULL
,	NULL
Oslo	NULL
,	NULL
Norway	NULL
.	NULL

Recombinant	NULL
staphylococcal	NULL
enterotoxin	NULL
A	NULL
(	NULL
SEA	NULL
)	NULL
was	NULL
expressed	NULL
in	NULL
Escherichia	NULL
coli	NULL
and	NULL
purified	NULL
to	NULL
homogeneity	NULL
as	NULL
described	NULL
.	NULL
``	NULL

The	NULL
protease	NULL
inhibitors	NULL
phenylmethyl	NULL
sulphonyl	NULL
fluoride	NULL
(	NULL
PMSF	NULL
)	NULL
,	NULL
leupeptine	NULL
,	NULL
pep-statin	NULL
,	NULL
aprotinin	NULL
and	NULL
bestatin	NULL
were	NULL
purchased	NULL
from	NULL
Boehringer	NULL
Mannheim	NULL
Scandinavia	NULL
AB	NULL
,	NULL
Bromma	NULL
,	NULL
Sweden	NULL
.	NULL

[	NULL
y-**p	NULL
]	NULL
ATP	NULL
was	NULL
purchased	NULL
from	NULL
Amersham	NULL
international	NULL
,	NULL
Amersham	NULL
,	NULL
UK	NULL
.	NULL

T4	NULL
polynucleotide	NULL
kinase	NULL
and	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
,	NULL
were	NULL
obtained	NULL
from	NULL
Pharmacia	NULL
biotech	NULL
Inc.	NULL
,	NULL
Piscataway	NULL
,	NULL
NJ	NULL
.	NULL

Tris-borate/EDTA	NULL
(	NULL
TBE	NULL
)	NULL
buffer	NULL
and	NULL
acrylamide/bis	NULL
29:1	NULL
were	NULL
purchased	NULL
from	NULL
Bio-rad	NULL
Laboratories	NULL
,	NULL
Upplands	NULL
Visby	NULL
,	NULL
Sweden	NULL
.	NULL

Gel	NULL
supershifts	NULL
were	NULL
performed	NULL
with	NULL
polyclonal	NULL
antibodies	NULL
against	NULL
c-Jun	NULL
,	NULL
Jun-B	NULL
,	NULL
Jun-D	NULL
,	NULL
c-Fos	NULL
,	NULL
pan-Fos	NULL
,	NULL
Fra-l	NULL
,	NULL
Fra-2	NULL
,	NULL
p.	NULL
50	NULL
,	NULL
p.	NULL
65	NULL
,	NULL
and	NULL
c-rel	NULL
purchased	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
,	NULL
Inc.	NULL
,	NULL
Santa	NULL
Cruz	NULL
,	NULL
CA	NULL
.	NULL

Transfected	NULL
cell	NULL
lines	NULL
Chinese	NULL
hamster	NULL
ovary	NULL
(	NULL
CHO	NULL
)	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
cDNA	NULL
encoding	NULL
human	NULL
leucocyte	NULL
antigen	NULL
(	NULL
HLA	NULL
)	NULL
-DR	NULL
and	NULL
B7	NULL
(	NULL
CHO-DR/B7	NULL
)	NULL
as	NULL
described	NULL
in	NULL
detail	NULL
elsewhere	NULL
``	NULL
and	NULL
used	NULL
as	NULL
©1997	NULL
Blackwell	NULL
Science	NULL
Ltd	NULL
,	NULL
Immunology	NULL
,	NULL
90	NULL
,	NULL
236-243	NULL
a	NULL
positive	NULL
control	NULL
in	NULL
the	NULL
CTLA-4	NULL
immunoglobulin	NULL
blocking	NULL
experiments	NULL
.	NULL

Cell	NULL
separation	NULL
Human	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
(	NULL
PBL	NULL
)	NULL
were	NULL
isolated	NULL
from	NULL
buffy	NULL
coats	NULL
by	NULL
centrifugation	NULL
on	NULL
Ficoll-Paque	NULL
and	NULL
Percoll	NULL
gradients	NULL
as	NULL
previously	NULL
described	NULL
.	NULL
``	NULL

CD4	NULL
and	NULL
CD8	NULL
positive	NULL
T	NULL
cells	NULL
were	NULL
purified	NULL
using	NULL
the	NULL
MACS	NULL
cell	NULL
sorting	NULL
system	NULL
,	NULL
Miltenyi	NULL
Biotec	NULL
Inc.	NULL
,	NULL
Auburn	NULL
,	NULL
CA	NULL
,	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
recommendations	NULL
.	NULL

The	NULL
purity	NULL
of	NULL
the	NULL
T	NULL
cells	NULL
regularly	NULL
exceeded	NULL
95	NULL
%	NULL
as	NULL
determined	NULL
by	NULL
fluorescence-activated	NULL
cell	NULL
sorting	NULL
(	NULL
FACS	NULL
)	NULL
analysis	NULL
.	NULL

The	NULL
purified	NULL
T	NULL
cells	NULL
were	NULL
resuspended	NULL
in	NULL
RPMI-1640	NULL
supplemented	NULL
with	NULL
2	NULL
mm	NULL
glutamine	NULL
and	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
FCS	NULL
)	NULL
(	NULL
complete	NULL
medium	NULL
)	NULL
.	NULL

Monoclonal	NULL
antibodies	NULL
linking	NULL
to	NULL
Dynabeads	NULL
Combinations	NULL
of	NULL
mAb	NULL
OKT-3/C215	NULL
OKT-3/A6H	NULL
,	NULL
OKT-3/	NULL
CD28	NULL
at	NULL
a	NULL
ratio	NULL
of	NULL
1:1	NULL
(	NULL
w/w	NULL
)	NULL
or	NULL
C215	NULL
and	NULL
OKT-3	NULL
alone	NULL
were	NULL
linked	NULL
to	NULL
Dynabeads	NULL
precoated	NULL
with	NULL
sheep	NULL
anti-mouse	NULL
IgG	NULL
,	NULL
as	NULL
described	NULL
earlier	NULL
.	NULL
``	NULL

Analysis	NULL
of	NULL
T-cell	NULL
activation	NULL
CD4	NULL
*	NULL
or	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
(	NULL
10°	NULL
)	NULL
and	NULL
mAb	NULL
coated	NULL
beads	NULL
(	NULL
1:5	NULL
x	NULL
10°	NULL
)	NULL
were	NULL
added	NULL
to	NULL
flat	NULL
bottomed	NULL
96-well	NULL
microtitre	NULL
plates	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
incubated	NULL
at	NULL
37°	NULL
for	NULL
3-10	NULL
days	NULL
and	NULL
analysed	NULL
for	NULL
surface	NULL
expression	NULL
of	NULL
IL-2R	NULL
«	NULL
,	NULL
-	NULL
$	NULL
,	NULL
-y	NULL
chains	NULL
,	NULL
CD71	NULL
,	NULL
B7-1	NULL
(	NULL
CD80	NULL
)	NULL
and	NULL
B7-2	NULL
(	NULL
CD86	NULL
)	NULL
on	NULL
a	NULL
FACScan	NULL
flow	NULL
cytometer	NULL
(	NULL
Becton	NULL
Dickinson	NULL
,	NULL
Mountain	NULL
View	NULL
,	NULL
CA	NULL
)	NULL
,	NULL
or	NULL
alternatively	NULL
labelled	NULL
with	NULL
[	NULL
°H	NULL
]	NULL
thymidine	NULL
during	NULL
the	NULL
last	NULL
4	NULL
hr	NULL
of	NULL
culture	NULL
and	NULL
analysed	NULL
for	NULL
DNA	NULL
synthesis	NULL
.	NULL

Radioactivity	NULL
was	NULL
measured	NULL
in	NULL
a	NULL
f-counter	NULL
.	NULL

B7	NULL
blocking	NULL
experiments	NULL
,	NULL
using	NULL
CTLA-4	NULL
immunoglobulin	NULL
at	NULL
10	NULL
ug/ml	NULL
,	NULL
CHO	NULL
cells	NULL
(	NULL
10*/well	NULL
)	NULL
transfected	NULL
with	NULL
HLA-DR	NULL
and	NULL
B7	NULL
(	NULL
CHO-DR/B7	NULL
)	NULL
were	NULL
used	NULL
as	NULL
a	NULL
positive	NULL
control	NULL
and	NULL
added	NULL
to	NULL
the	NULL
T	NULL
cells	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
0-1	NULL
ng/m	NULL
!	NULL

SEA	NULL
.	NULL

Nuclear	NULL
extracts	NULL
and	NULL
mobility	NULL
shift	NULL
assay	NULL
Freshly	NULL
isolated	NULL
resting	NULL
human	NULL
CD4*	NULL
or	NULL
CD8	NULL
*	NULL
positive	NULL
T	NULL
cells	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
4-6	NULL
x	NULL
10®/well	NULL
were	NULL
stimulated	NULL
with	NULL
OKT-3	NULL
or	NULL
C215	NULL
or	NULL
the	NULL
combinations	NULL
of	NULL
OKT-3/A6H	NULL
or	NULL
OKT-3/anti-CD28	NULL
mAb	NULL
linked	NULL
to	NULL
Dynabeads	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
using	NULL
a	NULL
previously	NULL
described	NULL
method	NULL
.	NULL
``	NULL

''	NULL
Briefly	NULL
,	NULL
the	NULL
T	NULL
cells	NULL
were	NULL
harvested	NULL
and	NULL
washed	NULL
in	NULL
10	NULL
ml	NULL
phosphate-buffered	NULL
saline	NULL
(	NULL
PBS	NULL
)	NULL
,	NULL
the	NULL
pellet	NULL
was	NULL
resuspended	NULL
in	NULL
1	NULL
ml	NULL
PBS	NULL
and	NULL
pelleted	NULL
again	NULL
by	NULL
spinning	NULL
for	NULL
15	NULL
s	NULL
in	NULL
a	NULL
microfuge	NULL
.	NULL

The	NULL
pellet	NULL
was	NULL
resupended	NULL
in	NULL
500	NULL
ul	NULL
cold	NULL
buffer	NULL
A	NULL
(	NULL
10	NULL
mm	NULL
Hepes	NULL
pH	NULL
7-9	NULL
;	NULL
10	NULL
mm	NULL
KCl	NULL
;	NULL
0-1	NULL
mm	NULL
ethylene	NULL
diamine	NULL
tetra-acetic	NULL
acid	NULL
(	NULL
EDTA	NULL
)	NULL
;	NULL
0-1	NULL
mm	NULL
egtazic	NULL
acid	NULL
(	NULL
EGTA	NULL
)	NULL
;	NULL
1	NULL
mm	NULL
dithiothreitol	NULL
(	NULL
DTT	NULL
)	NULL
;	NULL
0-5	NULL
mm	NULL
PMSF	NULL
)	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
allowed	NULL
to	NULL
swell	NULL
on	NULL
ice	NULL
for	NULL
15	NULL
min	NULL
,	NULL
25	NULL
ul	NULL
of	NULL
Nonidet-P40	NULL
(	NULL
NP-40	NULL
)	NULL
was	NULL
added	NULL
,	NULL
the	NULL
tubes	NULL
were	NULL
vigorously	NULL
vortexed	NULL
for	NULL
10	NULL
s	NULL
and	NULL
the	NULL
homogenate	NULL
centrifuged	NULL
.	NULL

The	NULL
nuclear	NULL
pellet	NULL
was	NULL
resuspended	NULL
in	NULL
100	NULL
pl	NULL
of	NULL
ice	NULL
cold	NULL
buffer	NULL
B	NULL
(	NULL
20	NULL
mm	NULL
hepes	NULL
pH	NULL
7-9	NULL
;	NULL
0-4	NULL
m	NULL
NaCl	NULL
;	NULL
1	NULL
mm	NULL
EDTA	NULL
;	NULL
l	NULL
mm	NULL
EGTA	NULL
;	NULL
1	NULL
mm	NULL
DTT	NULL
;	NULL
l	NULL
mm	NULL
PMSF	NULL
)	NULL
and	NULL
the	NULL
tube	NULL
was	NULL
rocked	NULL
for	NULL
15	NULL
min	NULL
at	NULL
4°	NULL
on	NULL
a	NULL
shaking	NULL
platform	NULL
.	NULL

The	NULL
nuclear	NULL
extract	NULL
was	NULL
centrifuged	NULL
for	NULL
5	NULL
min	NULL
at	NULL
4°	NULL
and	NULL
the	NULL
supernatant	NULL
was	NULL
frozen	NULL
in	NULL
aliquots	NULL
at	NULL
-70°	NULL
.	NULL

Binding	NULL
reactions	NULL
were	NULL
carried	NULL
out	NULL
by	NULL
diluting	NULL
(	NULL
3-5	NULL
ug/ul	NULL
)	NULL
of	NULL
nuclear	NULL
protein	NULL
in	NULL
binding	NULL
buffer	NULL
containing	NULL
2-3	NULL
ug	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
;	NULL
,	NULL
as	NULL
a	NULL
non-specific	NULL
competitor	NULL
,	NULL
and	NULL
,	NULL
15	NULL
x	NULL
10°	NULL
cpm	NULL
of	NULL
*°P	NULL
end	NULL
labelled	NULL
double-stranded	NULL
oligonucleotide	NULL
as	NULL
described	NULL
.	NULL
``	NULL

The	NULL
double	NULL
238	NULL
T.	NULL
Labuda	NULL
et	NULL
al	NULL
.	NULL

stranded	NULL
oligonucleotides	NULL
used	NULL
in	NULL
the	NULL
binding	NULL
assay	NULL
had	NULL
the	NULL
following	NULL
consensus	NULL
sequences	NULL
;	NULL
Oct-1	NULL
(	NULL
5CGT-CTCATGCGATGCAAATCACTTGAGATC3	NULL
'	NULL
)	NULL
,	NULL
AP-1	NULL
(	NULL
5'CT-AGTGATGAGT-CAGCCGGATC3	NULL
'	NULL
)	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
(	NULL
5GATCG-AGGGGACTTT-CCCTAGC3	NULL
'	NULL
)	NULL
.	NULL

RESULTS	NULL
A6H	NULL
costimulates	NULL
proliferation	NULL
of	NULL
CD4*	NULL
but	NULL
not	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
Purified	NULL
human	NULL
CD4*	NULL
T	NULL
cells	NULL
stimulated	NULL
with	NULL
OKT-3/A6H	NULL
beads	NULL
showed	NULL
a	NULL
strong	NULL
proliferative	NULL
response	NULL
reaching	NULL
peak	NULL
levels	NULL
at	NULL
day	NULL
5	NULL
of	NULL
stimulation	NULL
.	NULL

(	NULL
Fig	NULL
.	NULL

la	NULL
)	NULL
.	NULL

Surprisingly	NULL
,	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
did	NULL
not	NULL
respond	NULL
to	NULL
A6H	NULL
costimulation	NULL
(	NULL
Fig	NULL
.	NULL

1b	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
both	NULL
CD4*	NULL
and	NULL
CD8*	NULL
T	NULL
cells	NULL
showed	NULL
a	NULL
profound	NULL
proliferative	NULL
response	NULL
after	NULL
3	NULL
days	NULL
of	NULL
culture	NULL
when	NULL
stimulated	NULL
with	NULL
OKT-3/anti-CD28	NULL
beads	NULL
(	NULL
Fig	NULL
.	NULL

la	NULL
and	NULL
b	NULL
)	NULL
.	NULL

Effect	NULL
of	NULL
IL-2	NULL
on	NULL
T-cell	NULL
subsets	NULL
costimulated	NULL
with	NULL
A6H	NULL
We	NULL
reported	NULL
earlier	NULL
that	NULL
OKT-3/A6H	NULL
induced	NULL
activation	NULL
of	NULL
unfractionated	NULL
CD3	NULL
*	NULL
T	NULL
cells	NULL
resulted	NULL
in	NULL
increased	NULL
cell	NULL
size	NULL
and	NULL
up-regulation	NULL
of	NULL
the	NULL
IL-2R	NULL
«	NULL
chain	NULL
in	NULL
both	NULL
CD4*	NULL
and	NULL
CD8	NULL
*	NULL
subsets	NULL
.	NULL
``	NULL

These	NULL
results	NULL
together	NULL
with	NULL
the	NULL
fact	NULL
that	NULL
no	NULL
proliferative	NULL
response	NULL
was	NULL
seen	NULL
in	NULL
purified	NULL
CDS*	NULL
T	NULL
cells	NULL
costimulated	NULL
with	NULL
A6H	NULL
mAb	NULL
(	NULL
Fig	NULL
.	NULL

lb	NULL
)	NULL
,	NULL
suggests	NULL
that	NULL
when	NULL
unseparated	NULL
CD3+*	NULL
T	NULL
cells	NULL
are	NULL
costimulated	NULL
with	NULL
A6H	NULL
mAb	NULL
,	NULL
the	NULL
CD8	NULL
*	NULL
subpopulation	NULL
may	NULL
receive	NULL
growth	NULL
factors	NULL
supplied	NULL
by	NULL
activated	NULL
CD4*	NULL
T	NULL
cells	NULL
We	NULL
therefore	NULL
examined	NULL
the	NULL
role	NULL
of	NULL
the	NULL
IL-2R	NULL
pathway	NULL
in	NULL
activation	NULL
of	NULL
purified	NULL
T-cell	NULL
subpopula-tions	NULL
triggered	NULL
with	NULL
anti-CD3	NULL
mAb	NULL
and	NULL
costimulated	NULL
with	NULL
A6H	NULL
mAb	NULL
.	NULL

Addition	NULL
of	NULL
recombinant	NULL
IL-2	NULL
to	NULL
anti-CD3	NULL
stimulated	NULL
CD4*	NULL
or	NULL
CD8*	NULL
T	NULL
cells	NULL
induced	NULL
T-cell	NULL
proliferation	NULL
and	NULL
no	NULL
additional	NULL
effect	NULL
was	NULL
seen	NULL
with	NULL
A6H	NULL
or	NULL
CD28-costimulation	NULL
(	NULL
Fig	NULL
.	NULL

2a	NULL
and	NULL
b	NULL
)	NULL
.	NULL

Upregulation	NULL
of	NULL
surface	NULL
markers	NULL
on	NULL
T	NULL
cells	NULL
costimulated	NULL
with	NULL
mAb	NULL
A6H	NULL
To	NULL
investigate	NULL
the	NULL
regulation	NULL
of	NULL
cell	NULL
surface	NULL
activation	NULL
markers	NULL
,	NULL
in	NULL
purified	NULL
CD4*	NULL
or	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
,	NULL
we	NULL
analysed	NULL
expression	NULL
of	NULL
the	NULL
IL-2R	NULL
chains	NULL
,	NULL
CD71	NULL
and	NULL
B7	NULL
after	NULL
A6H	NULL
or	NULL
CD28	NULL
costimula-	NULL
-	NULL
&	NULL
-	NULL
A6H	NULL
-6-	NULL
CD28	NULL
~	NULL
-	NULL
#	NULL
-	NULL
C215	NULL
“	NULL
é	NULL
807	NULL
(	NULL
a	NULL
)	NULL
8071	NULL
(	NULL
b	NULL
)	NULL
x	NULL
€	NULL
60	NULL
60	NULL
a	NULL
2	NULL
40	NULL
40	NULL
.	NULL

$	NULL
£	NULL
20	NULL
20	NULL
[	NULL
<	NULL
a	NULL
<	NULL
0	NULL
0	NULL
Z	NULL
o	NULL
T	NULL
T	NULL
T	NULL
T	NULL
T	NULL
T	NULL
T	NULL
T	NULL
-r	NULL
T	NULL
0	NULL
_	NULL
3	NULL
5	NULL
7	NULL
10	NULL
0	NULL
-	NULL
3	NULL
5	NULL
7	NULL
10	NULL
Days	NULL
Figure	NULL
1	NULL
.	NULL

Kinetics	NULL
of	NULL
proliferation	NULL
of	NULL
costimulated	NULL
CD4*	NULL
(	NULL
a	NULL
)	NULL
or	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
(	NULL
b	NULL
)	NULL
.	NULL

Purified	NULL
T-cell	NULL
subsets	NULL
were	NULL
cultured	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
beads	NULL
coated	NULL
with	NULL
OKT-3	NULL
and	NULL
anti-CD28	NULL
,	NULL
A6H	NULL
or	NULL
C215	NULL
{	NULL
control	NULL
)	NULL
mAb	NULL
as	NULL
indicated	NULL
.	NULL

Proliferation	NULL
was	NULL
analysed	NULL
over	NULL
a	NULL
10	NULL
day	NULL
time	NULL
period	NULL
.	NULL

The	NULL
mean	NULL
value	NULL
+	NULL
SEM	NULL
from	NULL
triplicate	NULL
cultures	NULL
are	NULL
shown	NULL
.	NULL

One	NULL
representative	NULL
experiment	NULL
out	NULL
of	NULL
three	NULL
similar	NULL
.	NULL

H	NULL
AsH	NULL
[	NULL
§	NULL
A6H	NULL
+	NULL
IL-2	NULL
®	NULL
CD28	NULL
§	NULL
CD28	NULL
+	NULL
IL-2	NULL
E	NULL
C215	NULL
0	NULL
C215	NULL
+	NULL
!	NULL

L-2	NULL
5~	NULL
40	NULL
)	NULL
x	NULL
g	NULL
30	NULL
w	NULL
20	NULL
5.10	NULL
<	NULL
&	NULL
0	NULL
Figure	NULL
2	NULL
.	NULL

Proliferative	NULL
response	NULL
of	NULL
CD4*	NULL
(	NULL
a	NULL
)	NULL
or	NULL
CD8*	NULL
(	NULL
b	NULL
)	NULL
T	NULL
cells	NULL
coated	NULL
with	NULL
OKT-3	NULL
and	NULL
anti-CD28	NULL
,	NULL
A6H	NULL
or	NULL
C215	NULL
mAb	NULL
as	NULL
indicated	NULL
and	NULL
cultured	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
recombinant	NULL
IL-2	NULL
(	NULL
10	NULL
U/ml	NULL
)	NULL
for	NULL
5	NULL
days	NULL
.	NULL

The	NULL
mean	NULL
value+	NULL
SEM	NULL
of	NULL
triplicate	NULL
cultures	NULL
are	NULL
shown	NULL
.	NULL

One	NULL
out	NULL
of	NULL
two	NULL
similar	NULL
experiments	NULL
is	NULL
shown	NULL
.	NULL

tion	NULL
.	NULL

CD4*	NULL
T	NULL
cells	NULL
costimulated	NULL
with	NULL
A6H	NULL
expressed	NULL
high	NULL
amounts	NULL
of	NULL
IL-2R	NULL
#	NULL
,	NULL
-	NULL
$	NULL
,	NULL
-y	NULL
and	NULL
CD71	NULL
which	NULL
reached	NULL
similar	NULL
levels	NULL
as	NULL
CD28	NULL
costimulated	NULL
CD4*	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

Inter-estingly	NULL
,	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
costimulated	NULL
with	NULL
A6H	NULL
showed	NULL
a	NULL
higher	NULL
intensity	NULL
of	NULL
B7.1	NULL
and	NULL
B7.2	NULL
molecules	NULL
compared	NULL
to	NULL
T	NULL
cells	NULL
costimulated	NULL
with	NULL
anti-CD28	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
no	NULL
up-regulation	NULL
of	NULL
these	NULL
surface	NULL
markers	NULL
was	NULL
seen	NULL
on	NULL
A6H	NULL
costimulated	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
B7/CD28	NULL
pathway	NULL
is	NULL
not	NULL
contributing	NULL
to	NULL
A6H	NULL
costimulation	NULL
of	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
To	NULL
investigate	NULL
whether	NULL
the	NULL
late	NULL
proliferative	NULL
response	NULL
of	NULL
A6H-costimulated	NULL
T	NULL
cells	NULL
was	NULL
secondary	NULL
to	NULL
B7	NULL
up-regulation	NULL
on	NULL
the	NULL
T	NULL
cells	NULL
themselves	NULL
,	NULL
we	NULL
added	NULL
CTLA-4	NULL
immunoglobulin	NULL
to	NULL
block	NULL
the	NULL
CD28/B7	NULL
pathway	NULL
.	NULL

CTLA-4	NULL
immunoglobulin	NULL
efficiently	NULL
blocked	NULL
proliferation	NULL
of	NULL
T	NULL
cells	NULL
costimulated	NULL
with	NULL
B7	NULL
transfectants	NULL
but	NULL
did	NULL
not	NULL
influence	NULL
the	NULL
proliferative	NULL
response	NULL
in	NULL
A6H	NULL
costimulated	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

Expression	NULL
of	NULL
AP-1	NULL
and	NULL
NF-B	NULL
transcription	NULL
factors	NULL
in	NULL
A6H	NULL
costimulated	NULL
cells	NULL
The	NULL
AP-1	NULL
and	NULL
NF-xB	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
participate	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
a	NULL
number	NULL
of	NULL
immune	NULL
response	NULL
genes	NULL
including	NULL
the	NULL
IL-2	NULL
and	NULL
IL-2R	NULL
promoter	NULL
.	NULL

``	NULL
``	NULL
*	NULL
*	NULL
To	NULL
address	NULL
whether	NULL
the	NULL
differences	NULL
in	NULL
proliferation	NULL
and	NULL
cytokine	NULL
production	NULL
seen	NULL
in	NULL
A6H	NULL
versus	NULL
CD28	NULL
costimulated	NULL
T	NULL
cells	NULL
reflected	NULL
distinct	NULL
expression	NULL
of	NULL
the	NULL
AP-l	NULL
and	NULL
NF-xB	NULL
transcription	NULL
factors	NULL
,	NULL
we	NULL
used	NULL
a	NULL
gel	NULL
shift	NULL
assay	NULL
and	NULL
AP-	NULL
!	NULL

l	NULL
and	NULL
NF-kB	NULL
consensus	NULL
oligonucleotides	NULL
.	NULL

Resting	NULL
CD4*	NULL
T	NULL
cells	NULL
contained	NULL
minimal	NULL
amounts	NULL
of	NULL
AP-1	NULL
and	NULL
NF-xB	NULL
binding	NULL
proteins	NULL
in	NULL
the	NULL
nuclear	NULL
extracts	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

Low	NULL
levels	NULL
of	NULL
AP-l	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
proteins	NULL
were	NULL
induced	NULL
in	NULL
anti-CD3	NULL
stimulated	NULL
CD4*	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

Sa	NULL
,	NULL
b	NULL
,	NULL
d	NULL
and	NULL
e	NULL
)	NULL
and	NULL
the	NULL
amount	NULL
of	NULL
AP-1	NULL
binding	NULL
proteins	NULL
was	NULL
substantially	NULL
increased	NULL
in	NULL
A6H-costimu-lated	NULL
cells	NULL
after	NULL
1	NULL
or	NULL
3	NULL
days	NULL
of	NULL
stimulation	NULL
(	NULL
Fig	NULL
.	NULL

Sa	NULL
and	NULL
d	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
A6H	NULL
costimulation	NULL
had	NULL
no	NULL
additional	NULL
effect	NULL
on	NULL
NF-xB	NULL
compared	NULL
to	NULL
anti-CD3	NULL
stimulation	NULL
alone	NULL
(	NULL
Fig	NULL
.	NULL

5b	NULL
and	NULL
e	NULL
)	NULL
.	NULL

Strong	NULL
induction	NULL
of	NULL
both	NULL
AP-1	NULL
and	NULL
NF-xB	NULL
binding	NULL
proteins	NULL
was	NULL
seen	NULL
in	NULL
CD28	NULL
costimulated	NULL
cells	NULL
.	NULL

The	NULL
nuclear	NULL
extracts	NULL
©1997	NULL
Blackwell	NULL
Science	NULL
Ltd	NULL
,	NULL
Immunology	NULL
,	NULL
90	NULL
,	NULL
236-243	NULL
Costimulatory	NULL
effects	NULL
of	NULL
A6H	NULL
on	NULL
human	NULL
T	NULL
cells	NULL
239	NULL
CD4*	NULL
T	NULL
cost	NULL
T	NULL
IL-2Ra	NULL
IL-2Ra	NULL
.	NULL

Q	NULL
``	NULL
4	NULL
3	NULL
-	NULL
--	NULL
I	NULL
``	NULL
400	NULL
iof	NULL
10f	NULL
id	NULL
ast	NULL
40°	NULL
dol	NULL
iG	NULL
ao	NULL
ao	NULL
!	NULL

IL-2RB	NULL
IL-2R8	NULL
s	NULL
Llc	NULL
10°	NULL
gol	NULL
102	NULL
inm	NULL
aot	NULL
19°	NULL
go	NULL
!	NULL

1	NULL
10	NULL
104	NULL
IL-2Ry	NULL
IL-2Ry	NULL
100	NULL
0+	NULL
10	NULL
@	NULL
2	NULL
0	NULL
04	NULL
10°	NULL
dol	NULL
102	NULL
140	NULL
aot	NULL
CD71	NULL
CD71	NULL
100	NULL
gol	NULL
0	NULL
0	NULL
404	NULL
of	NULL
col	NULL
ot	NULL
inm	NULL
104	NULL
B7	NULL
(	NULL
CTLA-4	NULL
ig	NULL
)	NULL
B7	NULL
(	NULL
CTLA-4	NULL
Ig	NULL
)	NULL
10°	NULL
qo	NULL
)	NULL
%	NULL
98	NULL
1984	NULL
10°	NULL
dol	NULL
10	NULL
im	NULL
104	NULL
Log	NULL
fluorescence	NULL
intensity	NULL
B7-1	NULL
4	NULL
3	NULL
(	NULL
4	NULL
)	NULL
OKT-¥/A6H	NULL
(	NULL
3	NULL
)	NULL
OKT-¥CD28	NULL
2	NULL
(	NULL
2	NULL
)	NULL
OKT-3	NULL
1	NULL
(	NULL
1	NULL
)	NULL
cans	NULL
100	NULL
o	NULL
!	NULL

10	NULL
10	NULL
104	NULL
B7-2	NULL
4	NULL
3	NULL
2	NULL
1	NULL
100	NULL
gol	NULL
10	NULL
in	NULL
104	NULL
Log	NULL
fluorescence	NULL
intensity	NULL
Figure	NULL
3	NULL
.	NULL

Flow	NULL
cytometric	NULL
analysis	NULL
of	NULL
IL-2R4	NULL
,	NULL
IL-2R	NULL
$	NULL
,	NULL
IL-2Ry	NULL
,	NULL
CD71	NULL
,	NULL
B7	NULL
(	NULL
CTLA-4	NULL
immunoglobulin	NULL
)	NULL
,	NULL
B71	NULL
and	NULL
B72	NULL
on	NULL
CD4*	NULL
or	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
stimulated	NULL
with	NULL
mAb	NULL
coated	NULL
beads	NULL
,	NULL
as	NULL
shown	NULL
above	NULL
,	NULL
for	NULL
4	NULL
days	NULL
.	NULL

One	NULL
out	NULL
of	NULL
two	NULL
similar	NULL
experiments	NULL
is	NULL
shown	NULL
.	NULL

from	NULL
activated	NULL
CD4*	NULL
T	NULL
cells	NULL
contained	NULL
similar	NULL
amounts	NULL
of	NULL
proteins	NULL
binding	NULL
to	NULL
an	NULL
octamer	NULL
motif	NULL
,	NULL
showing	NULL
that	NULL
these	NULL
nuclear	NULL
extracts	NULL
were	NULL
intact	NULL
(	NULL
Fig	NULL
.	NULL

5¢c	NULL
and	NULL
f	NULL
)	NULL
.	NULL

To	NULL
verify	NULL
that	NULL
the	NULL
binding	NULL
to	NULL
AP-1	NULL
and	NULL
NF-xB	NULL
oligonucleotides	NULL
was	NULL
specific	NULL
,	NULL
we	NULL
©1997	NULL
Blackwell	NULL
Science	NULL
Ltd	NULL
,	NULL
Immunology	NULL
,	NULL
90	NULL
,	NULL
236-243	NULL
{	NULL
Q	NULL
okt-z/asH	NULL
W	NULL
CTLA-4	NULL
Ig	NULL
CD33-Fc	NULL
CTLA-4	NULL
CD33-Fc	NULL
0	NULL
20	NULL
40	NULL
60	NULL
80	NULL
DNA	NULL
synthesis	NULL
(	NULL
c.p.m	NULL
.	NULL

x	NULL
10°	NULL
)	NULL
Figure	NULL
4	NULL
.	NULL

Effect	NULL
of	NULL
CTLA-4	NULL
immunoglobulin	NULL
on	NULL
proliferation	NULL
of	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
stimulated	NULL
with	NULL
OKT-3	NULL
and	NULL
mAb	NULL
A6H	NULL
coated	NULL
beads	NULL
or	NULL
stimulated	NULL
with	NULL
CHO-DR/B7	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
SEA	NULL
(	NULL
0-1	NULL
ng/ml	NULL
)	NULL
for	NULL
5	NULL
days	NULL
.	NULL

CTLA-4	NULL
immunoglobulin	NULL
(	NULL
10	NULL
ug/ml	NULL
)	NULL
or	NULL
CD33Fc	NULL
(	NULL
10	NULL
ug/ml	NULL
,	NULL
control	NULL
immunoglobulin	NULL
fusion	NULL
protein	NULL
)	NULL
was	NULL
added	NULL
at	NULL
the	NULL
initiation	NULL
of	NULL
the	NULL
cultures	NULL
.	NULL

The	NULL
mean	NULL
value	NULL
+	NULL
SEM	NULL
of	NULL
triplicate	NULL
cultures	NULL
are	NULL
shown	NULL
.	NULL

One	NULL
out	NULL
of	NULL
two	NULL
similar	NULL
experiments	NULL
is	NULL
shown	NULL
.	NULL

performed	NULL
competition	NULL
experiments	NULL
with	NULL
unlabelled	NULL
oligonucleotides	NULL
.	NULL

AP-1	NULL
binding	NULL
activity	NULL
in	NULL
nuclear	NULL
extracts	NULL
from	NULL
CD4	NULL
positive	NULL
T	NULL
cells	NULL
,	NULL
costimulated	NULL
with	NULL
A6H	NULL
,	NULL
was	NULL
completely	NULL
blocked	NULL
by	NULL
a	NULL
50-fold	NULL
excess	NULL
of	NULL
unlabelled	NULL
AP-1	NULL
but	NULL
was	NULL
not	NULL
competed	NULL
by	NULL
excess	NULL
of	NULL
unlabelled	NULL
NF-xB	NULL
(	NULL
Fig	NULL
.	NULL

6a	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
was	NULL
specifically	NULL
competed	NULL
by	NULL
unlabelled	NULL
NF-xB	NULL
but	NULL
not	NULL
by	NULL
unlabelled	NULL
AP-1	NULL
(	NULL
Fig	NULL
.	NULL

6b	NULL
)	NULL
.	NULL

Characterization	NULL
of	NULL
AP-1	NULL
and	NULL
NF-xB	NULL
protein	NULL
components	NULL
in	NULL
costimulated	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
To	NULL
compare	NULL
the	NULL
composition	NULL
of	NULL
the	NULL
AP-1	NULL
and	NULL
NF-xB	NULL
binding	NULL
complexes	NULL
in	NULL
A6H	NULL
and	NULL
CD28	NULL
costimulated	NULL
CD4*	NULL
T	NULL
cells	NULL
,	NULL
we	NULL
performed	NULL
supershift	NULL
assay	NULL
with	NULL
antibodies	NULL
against	NULL
various	NULL
AP-1	NULL
family	NULL
members	NULL
(	NULL
c-Fos	NULL
,	NULL
Fra-1	NULL
,	NULL
Fra-2	NULL
,	NULL
Jun-D	NULL
,	NULL
Jun-B	NULL
and	NULL
c-Jun	NULL
)	NULL
and	NULL
Rel	NULL
family	NULL
members	NULL
(	NULL
p50	NULL
,	NULL
p65	NULL
and	NULL
c-Rel	NULL
)	NULL
.	NULL

The	NULL
AP-1	NULL
binding	NULL
complex	NULL
in	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
costimulated	NULL
with	NULL
A6H	NULL
was	NULL
partially	NULL
blocked	NULL
by	NULL
antibodies	NULL
against	NULL
Fra-2	NULL
,	NULL
Jun-D	NULL
,	NULL
Jun-B	NULL
and	NULL
c-Jun	NULL
(	NULL
Fig	NULL
.	NULL

7a	NULL
)	NULL
.	NULL

The	NULL
AP-1	NULL
complex	NULL
in	NULL
CD28	NULL
costimulated	NULL
T	NULL
cells	NULL
contained	NULL
these	NULL
Fos/Jun	NULL
proteins	NULL
as	NULL
well	NULL
as	NULL
Fra-l	NULL
(	NULL
Fig	NULL
.	NULL

7b	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
all	NULL
AP-l	NULL
DNA	NULL
binding	NULL
complexes	NULL
seemed	NULL
to	NULL
contain	NULL
at	NULL
least	NULL
one	NULL
Fos	NULL
family	NULL
member	NULL
,	NULL
since	NULL
antibodies	NULL
recognizing	NULL
all	NULL
members	NULL
of	NULL
the	NULL
Fos	NULL
family	NULL
completely	NULL
blocked	NULL
the	NULL
AP-1	NULL
complex	NULL
(	NULL
Fig	NULL
.	NULL

7a	NULL
and	NULL
b	NULL
)	NULL
.	NULL

Supershift	NULL
of	NULL
the	NULL
NF-xB	NULL
complex	NULL
in	NULL
A6H	NULL
or	NULL
CD28	NULL
costimulated	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
indicated	NULL
that	NULL
a	NULL
major	NULL
part	NULL
of	NULL
the	NULL
complex	NULL
contained	NULL
pS50-p50	NULL
homodimers	NULL
,	NULL
since	NULL
it	NULL
was	NULL
shifted	NULL
and	NULL
blocked	NULL
by	NULL
anti-p50	NULL
antibodies	NULL
.	NULL

Part	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
xB	NULL
complex	NULL
in	NULL
A6H	NULL
and	NULL
CD28	NULL
costimulated	NULL
T	NULL
cells	NULL
contained	NULL
c-Rel	NULL
,	NULL
whereas	NULL
only	NULL
an	NULL
marginal	NULL
effect	NULL
was	NULL
seen	NULL
with	NULL
p65	NULL
antibodies	NULL
(	NULL
Fig	NULL
.	NULL

7¢	NULL
and	NULL
d	NULL
)	NULL
.	NULL

The	NULL
antibodies	NULL
used	NULL
were	NULL
functional	NULL
since	NULL
we	NULL
have	NULL
shown	NULL
that	NULL
they	NULL
efficiently	NULL
supershift	NULL
or	NULL
block	NULL
the	NULL
binding	NULL
of	NULL
nuclear	NULL
extracts	NULL
from	NULL
superantigen	NULL
(	NULL
sAg	NULL
)	NULL
-stimulated	NULL
T	NULL
cells	NULL
to	NULL
the	NULL
AP-1	NULL
or	NULL
NF-	NULL
«	NULL
B	NULL
element	NULL
,	NULL
respectively	NULL
.	NULL
``	NULL

The	NULL
effect	NULL
of	NULL
the	NULL
antibodies	NULL
was	NULL
specific	NULL
since	NULL
no	NULL
direct	NULL
binding	NULL
to	NULL
the	NULL
probe	NULL
was	NULL
seen	NULL
and	NULL
no	NULL
influence	NULL
on	NULL
the	NULL
gelshift	NULL
of	NULL
an	NULL
irrelevant	NULL
nuclear	NULL
complex	NULL
was	NULL
recorded	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

240	NULL
T.	NULL
Labuda	NULL
et	NULL
al	NULL
.	NULL

APA-	NULL
>	NULL
Free	NULL
oligo-	NULL
>	NULL
Free	NULL
oligo-	NULL
>	NULL
(	NULL
e	NULL
)	NULL
NF-xB	NULL
-	NULL
>	NULL
Free	NULL
oligo	NULL
~	NULL
>	NULL
Free	NULL
oligo-	NULL
>	NULL
oct-1-p	NULL
>	NULL
|	NULL
oct-2-	NULL
>	NULL
Free	NULL
oligo	NULL
-	NULL
>	NULL
®	NULL
OCT-1	NULL
-	NULL
>	NULL
OCT-2-L	NULL
>	NULL
Free	NULL
oligo-	NULL
>	NULL
Figure	NULL
5	NULL
.	NULL

Electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
were	NULL
performed	NULL
with	NULL
nuclear	NULL
extracts	NULL
from	NULL
CD4*	NULL
T	NULL
cells	NULL
cultured	NULL
for	NULL
24	NULL
hr	NULL
(	NULL
a	NULL
,	NULL
b	NULL
and	NULL
c	NULL
)	NULL
or	NULL
72	NULL
hr	NULL
(	NULL
d	NULL
,	NULL
e	NULL
and	NULL
f	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
beads	NULL
coated	NULL
with	NULL
mAb	NULL
as	NULL
indicated	NULL
,	NULL
(	NULL
a	NULL
through	NULL
f	NULL
)	NULL
.	NULL

Lane	NULL
1	NULL
indicates	NULL
free	NULL
probe	NULL
without	NULL
cell	NULL
extract	NULL
.	NULL

Oligonucleotides	NULL
containing	NULL
AP-1	NULL
(	NULL
a	NULL
and	NULL
d	NULL
)	NULL
,	NULL
NF-xB	NULL
(	NULL
b	NULL
and	NULL
e	NULL
)	NULL
or	NULL
Oct-l	NULL
(	NULL
c	NULL
and	NULL
f	NULL
)	NULL
consensus	NULL
motifs	NULL
were	NULL
labelled	NULL
with	NULL
[	NULL
y*	NULL
@	NULL
ATP	NULL
]	NULL
and	NULL
used	NULL
for	NULL
gelshift	NULL
analysis	NULL
.	NULL

One	NULL
representative	NULL
experiment	NULL
out	NULL
of	NULL
three	NULL
similar	NULL
.	NULL

(	NULL
a	NULL
)	NULL
Competitor	NULL
(	NULL
b	NULL
)	NULL
Competitor	NULL
AP-1	NULL
NF-kB	NULL
AP-1	NULL
NF-kB	NULL
F	NULL
0	NULL
50	NULL
50	NULL
B	NULL
woe	NULL
wom	NULL
may	NULL
:	NULL
_E	NULL
o_	NULL
50	NULL
50	NULL
AP-1	NULL
-	NULL
``	NULL
NF-kB	NULL
-	NULL
>	NULL
Free	NULL
oligo	NULL
-	NULL
>	NULL
Free	NULL
oligo	NULL
-	NULL
>	NULL
Figure	NULL
6	NULL
.	NULL

Sequence	NULL
specificity	NULL
of	NULL
AP-1	NULL
(	NULL
a	NULL
)	NULL
and	NULL
NF-xB	NULL
(	NULL
b	NULL
)	NULL
binding	NULL
activities	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
incubated	NULL
with	NULL
radiolabelled	NULL
AP-1	NULL
(	NULL
a	NULL
)	NULL
or	NULL
NF-xB	NULL
(	NULL
b	NULL
)	NULL
consensus	NULL
oligonucleotides	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
competitor	NULL
(	NULL
0	NULL
)	NULL
or	NULL
the	NULL
presence	NULL
of	NULL
50	NULL
x	NULL
molar	NULL
excess	NULL
of	NULL
unlabelled	NULL
AP-1	NULL
and	NULL
NF-xB	NULL
,	NULL
respectively	NULL
.	NULL

Free	NULL
probe	NULL
without	NULL
cell	NULL
extract	NULL
is	NULL
shown	NULL
in	NULL
(	NULL
f	NULL
)	NULL
.	NULL

One	NULL
out	NULL
of	NULL
two	NULL
similar	NULL
experiments	NULL
is	NULL
shown	NULL
.	NULL

Inability	NULL
of	NULL
A6H	NULL
mAb	NULL
to	NULL
induce	NULL
AP-1	NULL
activity	NULL
in	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
To	NULL
investigate	NULL
whether	NULL
the	NULL
failure	NULL
of	NULL
A6H	NULL
mAb	NULL
to	NULL
induce	NULL
CD8*	NULL
T-cell	NULL
proliferation	NULL
was	NULL
due	NULL
to	NULL
an	NULL
inability	NULL
to	NULL
mobilize	NULL
the	NULL
AP-1	NULL
nuclear	NULL
factor	NULL
,	NULL
we	NULL
performed	NULL
gelshift	NULL
on	NULL
nuclear	NULL
extracts	NULL
from	NULL
purified	NULL
CD8*	NULL
T	NULL
cells	NULL
.	NULL

No	NULL
induction	NULL
of	NULL
AP-1	NULL
was	NULL
seen	NULL
in	NULL
CD8*	NULL
T	NULL
cells	NULL
costimulated	NULL
with	NULL
A6H	NULL
mAb	NULL
(	NULL
Fig	NULL
.	NULL

8a	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
A6H	NULL
costimulated	NULL
CD4*	NULL
T	NULL
cells	NULL
contained	NULL
substantial	NULL
amounts	NULL
of	NULL
AP-1	NULL
binding	NULL
proteins	NULL
.	NULL

Low	NULL
levels	NULL
of	NULL
NF-kB	NULL
binding	NULL
protein	NULL
were	NULL
induced	NULL
in	NULL
the	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
stimulated	NULL
with	NULL
OKT-3	NULL
alone	NULL
and	NULL
no	NULL
additional	NULL
effect	NULL
was	NULL
seen	NULL
with	NULL
A6H	NULL
costimulation	NULL
(	NULL
Fig	NULL
.	NULL

8b	NULL
)	NULL
In	NULL
contrast	NULL
,	NULL
CD28	NULL
costimulation	NULL
induced	NULL
similar	NULL
amounts	NULL
of	NULL
AP-1	NULL
binding	NULL
proteins	NULL
in	NULL
both	NULL
the	NULL
CD4*	NULL
and	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

Sa	NULL
)	NULL
.	NULL

The	NULL
amount	NULL
of	NULL
OCT-1	NULL
binding	NULL
protein	NULL
present	NULL
in	NULL
the	NULL
CD8*	NULL
and	NULL
CD4	NULL
*	NULL
T	NULL
cell	NULL
populations	NULL
,	NULL
respectively	NULL
,	NULL
was	NULL
similar	NULL
irrespective	NULL
of	NULL
the	NULL
stimuli	NULL
used	NULL
(	NULL
Fig	NULL
.	NULL

8¢	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

DISCUSSION	NULL
A6H	NULL
mAb	NULL
recognizes	NULL
an	NULL
antigen	NULL
that	NULL
is	NULL
expressed	NULL
on	NULL
85-90	NULL
%	NULL
of	NULL
CD4*	NULL
and	NULL
CD8*	NULL
T	NULL
cells	NULL
as	NULL
well	NULL
as	NULL
on	NULL
certain	NULL
carcinoma	NULL
cells	NULL
.	NULL

In	NULL
the	NULL
present	NULL
study	NULL
we	NULL
show	NULL
that	NULL
binding	NULL
of	NULL
A6H	NULL
mAb	NULL
results	NULL
in	NULL
proliferation	NULL
of	NULL
CD3	NULL
triggered	NULL
CD4*	NULL
T	NULL
cells	NULL
.	NULL

Unexpectedly	NULL
,	NULL
no	NULL
proliferative	NULL
response	NULL
was	NULL
observed	NULL
in	NULL
the	NULL
CD8	NULL
*	NULL
T-cell	NULL
population	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
A6H	NULL
,	NULL
no	NULL
previously	NULL
described	NULL
costimulatory	NULL
molecule	NULL
expressed	NULL
at	NULL
similar	NULL
densities	NULL
on	NULL
both	NULL
CD4*	NULL
and	NULL
CD8	NULL
#	NULL
*	NULL
T	NULL
cells	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
costimulatory	NULL
for	NULL
only	NULL
one	NULL
subset	NULL
.	NULL

This	NULL
includes	NULL
CD28	NULL
,	NULL
LFA-1	NULL
,	NULL
CD2	NULL
and	NULL
VLA-4	NULL
which	NULL
are	NULL
expressed	NULL
on	NULL
all	NULL
or	NULL
a	NULL
majority	NULL
of	NULL
Tcells*	NULL
``	NULL
``	NULL
and	NULL
are	NULL
costimulatory	NULL
for	NULL
both	NULL
CD4*	NULL
and	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
.	NULL
``	NULL

Costimulation	NULL
of	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
with	NULL
A6H	NULL
resulted	NULL
in	NULL
strong	NULL
up-regulation	NULL
of	NULL
IL-2R	NULL
a	NULL
,	NULL
-	NULL
#	NULL
and	NULL
-y	NULL
chains	NULL
whereas	NULL
no	NULL
IL-2R	NULL
expression	NULL
was	NULL
seen	NULL
in	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
after	NULL
A6H	NULL
costimulation	NULL
,	NULL
showing	NULL
that	NULL
A6H	NULL
costimulation	NULL
is	NULL
sufficient	NULL
to	NULL
induce	NULL
all	NULL
chains	NULL
of	NULL
the	NULL
high	NULL
affinity	NULL
IL-2R	NULL
on	NULL
CD4*	NULL
T	NULL
cells	NULL
.	NULL

CD4*	NULL
or	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
stimulated	NULL
with	NULL
anti-CD3	NULL
mAb	NULL
alone	NULL
expressed	NULL
only	NULL
marginal	NULL
amounts	NULL
of	NULL
the	NULL
IL-2R	NULL
chains	NULL
and	NULL
failed	NULL
to	NULL
proliferate	NULL
.	NULL

However	NULL
,	NULL
the	NULL
addition	NULL
of	NULL
rIL-2	NULL
was	NULL
sufficient	NULL
to	NULL
induce	NULL
responsiveness	NULL
in	NULL
both	NULL
CD4*	NULL
and	NULL
CD8*	NULL
T	NULL
cells	NULL
We	NULL
©1997	NULL
Blackwell	NULL
Science	NULL
Ltd	NULL
,	NULL
Immunology	NULL
,	NULL
90	NULL
,	NULL
236-243	NULL
Costimulatory	NULL
effects	NULL
of	NULL
A6H	NULL
on	NULL
human	NULL
T	NULL
cells	NULL
241	NULL
Free	NULL
oligo-	NULL
[	NULL
>	NULL
Free	NULL
oligo	NULL
-	NULL
>	NULL
Po	NULL
A	NULL
%	NULL
Q	NULL
®	NULL
8	NULL
d	NULL
C	NULL
.S	NULL
``	NULL
«	NULL
«	NULL
C	NULL
C	NULL
COW	NULL
8	NULL
&	NULL
S	NULL
«	NULL
&	NULL
Q	NULL
‘	NULL
OVO	NULL
(	NULL
y	NULL
o	NULL
&	NULL
28	NULL
¢	NULL
$	NULL
52	NULL
3°	NULL
*	NULL
*	NULL
O	NULL
«	NULL
C	NULL
w	NULL
@	NULL
$	NULL
``	NULL
&	NULL
&	NULL
Q	NULL
’	NULL
b	NULL
Super	NULL
shift	NULL
-	NULL
>	NULL
NF-kB	NULL
-	NULL
>	NULL
Free	NULL
oligo	NULL
-	NULL
>	NULL
(	NULL
d	NULL
)	NULL
Super	NULL
shift	NULL
-	NULL
>	NULL
NF-xB	NULL
-	NULL
>	NULL
Free	NULL
oligo-	NULL
>	NULL
Figure	NULL
7	NULL
.	NULL

Analysis	NULL
of	NULL
the	NULL
composition	NULL
of	NULL
AP-1	NULL
(	NULL
a	NULL
and	NULL
b	NULL
)	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
(	NULL
c	NULL
and	NULL
d	NULL
)	NULL
DNA	NULL
binding	NULL
complexes	NULL
from	NULL
CD4*	NULL
T	NULL
cells	NULL
stimulated	NULL
with	NULL
OKT-3	NULL
and	NULL
costimulated	NULL
with	NULL
A6H	NULL
(	NULL
a	NULL
and	NULL
c	NULL
)	NULL
or	NULL
anti-CD28	NULL
(	NULL
b	NULL
and	NULL
d	NULL
)	NULL
for	NULL
72	NULL
hr	NULL
.	NULL

The	NULL
nuclear	NULL
extracts	NULL
were	NULL
pre-incubated	NULL
for	NULL
20	NULL
min	NULL
with	NULL
different	NULL
antibodies	NULL
against	NULL
the	NULL
various	NULL
Jun/Fos	NULL
family	NULL
members	NULL
as	NULL
indicated	NULL
(	NULL
a	NULL
and	NULL
b	NULL
)	NULL
or	NULL
Rel	NULL
family	NULL
members	NULL
(	NULL
c	NULL
and	NULL
d	NULL
)	NULL
before	NULL
addition	NULL
of	NULL
a	NULL
*°P	NULL
labelled	NULL
AP-1	NULL
or	NULL
NF-xB	NULL
oligonucleotide	NULL
and	NULL
run	NULL
in	NULL
a	NULL
EMSA	NULL
.	NULL

One	NULL
representative	NULL
experiment	NULL
out	NULL
of	NULL
three	NULL
similar	NULL
is	NULL
shown	NULL
.	NULL

AP-1	NULL
-	NULL
>	NULL
Free	NULL
oligo	NULL
--	NULL
>	NULL
NF-	NULL
«	NULL
xB	NULL
-	NULL
>	NULL
Free	NULL
oligo-	NULL
iw	NULL
Figure	NULL
8	NULL
.	NULL

Induction	NULL
of	NULL
AP-1	NULL
(	NULL
a	NULL
)	NULL
NF-xB	NULL
(	NULL
b	NULL
)	NULL
or	NULL
Oct-1	NULL
(	NULL
c	NULL
)	NULL
in	NULL
CD4	NULL
*	NULL
(	NULL
a	NULL
lanes	NULL
2-5	NULL
)	NULL
or	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
(	NULL
a	NULL
lanes	NULL
6-9	NULL
,	NULL
b	NULL
and	NULL
c	NULL
)	NULL
.	NULL

Purified	NULL
populations	NULL
of	NULL
human	NULL
T	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
beads	NULL
as	NULL
indicated	NULL
for	NULL
24	NULL
hr	NULL
before	NULL
nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
and	NULL
used	NULL
in	NULL
gel	NULL
shift	NULL
analysis	NULL
.	NULL

Free	NULL
probe	NULL
without	NULL
cell	NULL
extract	NULL
is	NULL
shown	NULL
in	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
.	NULL

One	NULL
out	NULL
of	NULL
two	NULL
similar	NULL
experiments	NULL
is	NULL
shown	NULL
.	NULL

©1997	NULL
Blackwell	NULL
Science	NULL
Ltd	NULL
,	NULL
Immunology	NULL
,	NULL
90	NULL
,	NULL
236-243	NULL
have	NULL
previously	NULL
reported	NULL
an	NULL
increase	NULL
in	NULL
IL-2R	NULL
«	NULL
expression	NULL
on	NULL
both	NULL
CD4*	NULL
and	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
when	NULL
unseparated	NULL
CD3	NULL
*	NULL
T	NULL
cells	NULL
were	NULL
co-stimulated	NULL
with	NULL
A6H	NULL
mAb	NULL
.	NULL
``	NULL

However	NULL
,	NULL
the	NULL
present	NULL
results	NULL
indicates	NULL
that	NULL
the	NULL
up-regulation	NULL
of	NULL
IL-2R	NULL
«	NULL
on	NULL
the	NULL
CD8*	NULL
T-cell	NULL
subpopulation	NULL
,	NULL
seen	NULL
in	NULL
the	NULL
previous	NULL
study	NULL
,	NULL
most	NULL
likely	NULL
was	NULL
dependent	NULL
on	NULL
paracrine	NULL
IL-2	NULL
production	NULL
from	NULL
activated	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
.	NULL

A6H	NULL
costimulation	NULL
of	NULL
CD4*	NULL
T	NULL
cells	NULL
resulted	NULL
in	NULL
the	NULL
up-regulation	NULL
of	NULL
B7	NULL
molecules	NULL
that	NULL
reached	NULL
levels	NULL
somewhat	NULL
higher	NULL
than	NULL
those	NULL
obtained	NULL
with	NULL
CD28	NULL
costimulation	NULL
.	NULL

These	NULL
results	NULL
suggested	NULL
a	NULL
possible	NULL
role	NULL
for	NULL
B7	NULL
on	NULL
T	NULL
cells	NULL
as	NULL
a	NULL
costimulatory	NULL
molecule	NULL
in	NULL
T-T	NULL
cell	NULL
interactions	NULL
.	NULL

However	NULL
,	NULL
CTLA-4	NULL
immunoglobulin	NULL
did	NULL
not	NULL
block	NULL
the	NULL
costimulatory	NULL
signal	NULL
induced	NULL
in	NULL
A6H	NULL
cultures	NULL
,	NULL
demonstrating	NULL
that	NULL
A6H	NULL
ligation	NULL
acts	NULL
via	NULL
a	NULL
costimulatory	NULL
pathway	NULL
that	NULL
is	NULL
independent	NULL
of	NULL
the	NULL
B7-CD28	NULL
interaction	NULL
.	NULL

B7-2	NULL
(	NULL
CD86	NULL
)	NULL
is	NULL
constitutively	NULL
expressed	NULL
on	NULL
dendritic	NULL
cells	NULL
and	NULL
B	NULL
cells	NULL
and	NULL
is	NULL
regarded	NULL
as	NULL
the	NULL
major	NULL
costimulatory	NULL
molecule	NULL
during	NULL
the	NULL
initiation	NULL
of	NULL
an	NULL
immune	NULL
response	NULL
.	NULL
``	NULL

''	NULL
Yet	NULL
,	NULL
little	NULL
is	NULL
known	NULL
about	NULL
the	NULL
function	NULL
of	NULL
B7	NULL
as	NULL
a	NULL
costimulatory	NULL
ligand	NULL
in	NULL
T-T	NULL
cell	NULL
interactions	NULL
.	NULL

In	NULL
the	NULL
case	NULL
of	NULL
A6H	NULL
costimulation	NULL
,	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
up-regulation	NULL
of	NULL
B7-1	NULL
and	NULL
2	NULL
on	NULL
the	NULL
T	NULL
cells	NULL
may	NULL
occur	NULL
when	NULL
primary	NULL
activated	NULL
T	NULL
cells	NULL
are	NULL
in	NULL
a	NULL
refractory	NULL
phase	NULL
and	NULL
therefore	NULL
are	NULL
unable	NULL
to	NULL
respond	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
B7	NULL
on	NULL
these	NULL
cells	NULL
may	NULL
,	NULL
however	NULL
,	NULL
participate	NULL
in	NULL
costimulation	NULL
during	NULL
a	NULL
secondary	NULL
immune	NULL
response	NULL
.	NULL

The	NULL
cytokine	NULL
profile	NULL
after	NULL
A6H	NULL
costimulation	NULL
included	NULL
moderate	NULL
levels	NULL
of	NULL
IL-2	NULL
production	NULL
in	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
.	NULL
``	NULL

In	NULL
contrast	NULL
,	NULL
no	NULL
proliferation	NULL
or	NULL
IL-2	NULL
production	NULL
was	NULL
seen	NULL
in	NULL
A6H	NULL
costimulated	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
.	NULL

Several	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
the	NULL
production	NULL
of	NULL
IL-2	NULL
is	NULL
regulated	NULL
mainly	NULL
at	NULL
the	NULL
transcrip-	NULL
242	NULL
T.	NULL
Labuda	NULL
et	NULL
al	NULL
.	NULL

tional	NULL
level	NULL
and	NULL
regulation	NULL
of	NULL
the	NULL
IL-2	NULL
enhancer/promoter	NULL
region	NULL
is	NULL
a	NULL
critical	NULL
step	NULL
in	NULL
control	NULL
of	NULL
T-cell	NULL
growth	NULL
.	NULL

'~	NULL
``	NULL
The	NULL
300	NULL
bp	NULL
region	NULL
upstream	NULL
of	NULL
the	NULL
transcription	NULL
start	NULL
site	NULL
of	NULL
the	NULL
IL-2	NULL
enhancer/promoter	NULL
contain	NULL
binding	NULL
motifs	NULL
for	NULL
Oct-1	NULL
,	NULL
NF-xB	NULL
,	NULL
AP-1	NULL
and	NULL
NF-AT	NULL
transcription	NULL
factors	NULL
.	NULL

'*	NULL
``	NULL
'	NULL
The	NULL
AP-1	NULL
and	NULL
NF-	NULL
«	NULL
xB	NULL
transcription	NULL
factors	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
a	NULL
variety	NULL
of	NULL
genes	NULL
involved	NULL
in	NULL
inflammatory	NULL
and	NULL
immune	NULL
responses	NULL
including	NULL
IL-2	NULL
,	NULL
IL-2R	NULL
,	NULL
TNF	NULL
and	NULL
c-myc.26	NULL
*	NULL
Costimulation	NULL
with	NULL
A6H	NULL
induced	NULL
large	NULL
amounts	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
AP-1	NULL
but	NULL
did	NULL
not	NULL
affect	NULL
NF-	NULL
«	NULL
xB	NULL
levels	NULL
.	NULL

Furthermore	NULL
,	NULL
induction	NULL
of	NULL
AP-1	NULL
required	NULL
costimulation	NULL
at	NULL
the	NULL
early	NULL
time	NULL
points	NULL
but	NULL
was	NULL
induced	NULL
at	NULL
low	NULL
levels	NULL
with	NULL
anti-CD3	NULL
stimulation	NULL
alone	NULL
at	NULL
later	NULL
time	NULL
points	NULL
studied	NULL
.	NULL

However	NULL
,	NULL
A6H	NULL
costimulation	NULL
augmented	NULL
induction	NULL
of	NULL
AP-1	NULL
at	NULL
all	NULL
studied	NULL
time	NULL
points	NULL
.	NULL

CD3	NULL
stimulation	NULL
alone	NULL
was	NULL
sufficient	NULL
for	NULL
induction	NULL
of	NULL
substantial	NULL
amounts	NULL
of	NULL
NF-kB	NULL
during	NULL
the	NULL
early	NULL
phase	NULL
of	NULL
the	NULL
response	NULL
.	NULL

The	NULL
induction	NULL
was	NULL
not	NULL
further	NULL
increased	NULL
by	NULL
A6H	NULL
costimulation	NULL
,	NULL
whereas	NULL
CD28	NULL
costimulation	NULL
induced	NULL
a	NULL
prominent	NULL
increase	NULL
in	NULL
NF-xB	NULL
binding	NULL
protein	NULL
.	NULL

This	NULL
is	NULL
consistent	NULL
with	NULL
earlier	NULL
studies	NULL
suggesting	NULL
that	NULL
signal	NULL
1	NULL
is	NULL
sufficient	NULL
for	NULL
induction	NULL
of	NULL
NF-xB	NULL
whereas	NULL
induction	NULL
of	NULL
AP-1	NULL
requires	NULL
costimulation	NULL
during	NULL
the	NULL
early	NULL
phase	NULL
of	NULL
an	NULL
immune	NULL
response	NULL
.	NULL

``	NULL
**	NULL
>	NULL
Supershift	NULL
analysis	NULL
revealed	NULL
minor	NULL
differences	NULL
in	NULL
the	NULL
composition	NULL
of	NULL
the	NULL
AP-1	NULL
complex	NULL
in	NULL
A6H	NULL
and	NULL
CD28	NULL
costimulated	NULL
T	NULL
cells	NULL
.	NULL

CD4	NULL
*	NULL
T	NULL
cells	NULL
contained	NULL
Fra-2	NULL
,	NULL
Jun-D	NULL
,	NULL
Jun-B	NULL
and	NULL
c-Jun	NULL
proteins	NULL
whereas	NULL
CD28	NULL
costimulation	NULL
induced	NULL
an	NULL
additional	NULL
protein	NULL
,	NULL
Fra-1	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
the	NULL
composition	NULL
of	NULL
the	NULL
AP-1	NULL
proteins	NULL
may	NULL
change	NULL
depending	NULL
on	NULL
the	NULL
stimuli	NULL
used	NULL
to	NULL
activate	NULL
the	NULL
T	NULL
cells	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
majority	NULL
of	NULL
the	NULL
AP-1	NULL
binding	NULL
proteins	NULL
seemed	NULL
to	NULL
exist	NULL
as	NULL
Fos-Jun	NULL
heterodimers	NULL
and	NULL
not	NULL
as	NULL
Jun-Jun	NULL
homodimers	NULL
since	NULL
antibodies	NULL
against	NULL
pan-Fos	NULL
proteins	NULL
abrogated	NULL
all	NULL
DNA	NULL
binding	NULL
activity	NULL
regardless	NULL
of	NULL
the	NULL
costimulatory	NULL
pathway	NULL
(	NULL
e.g	NULL
.	NULL

CD28	NULL
or	NULL
A6H	NULL
costimulation	NULL
)	NULL
.	NULL

This	NULL
is	NULL
in	NULL
agreement	NULL
with	NULL
earlier	NULL
results	NULL
revealing	NULL
that	NULL
the	NULL
dimerization	NULL
affinities	NULL
of	NULL
Fos-Jun	NULL
heterodimers	NULL
are	NULL
much	NULL
higher	NULL
than	NULL
those	NULL
of	NULL
Jun-Jun	NULL
homodimers	NULL
and	NULL
heterodimers	NULL
promotes	NULL
more	NULL
effective	NULL
DNA	NULL
binding	NULL
and	NULL
transactivating	NULL
properties.3435	NULL
4	NULL
The	NULL
composition	NULL
of	NULL
the	NULL
NF-xB	NULL
complex	NULL
after	NULL
A6H	NULL
or	NULL
CD28	NULL
costimulation	NULL
of	NULL
CD4*	NULL
T	NULL
cells	NULL
was	NULL
similar	NULL
.	NULL

A	NULL
major	NULL
part	NULL
contained	NULL
p50-p50	NULL
homodimers	NULL
and	NULL
moderate	NULL
amounts	NULL
of	NULL
c-rel	NULL
and	NULL
low	NULL
amounts	NULL
of	NULL
p65	NULL
were	NULL
present	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
observed	NULL
quantitative	NULL
differences	NULL
in	NULL
NF-xB	NULL
expression	NULL
may	NULL
be	NULL
related	NULL
to	NULL
the	NULL
increased	NULL
ability	NULL
of	NULL
CD28	NULL
compared	NULL
to	NULL
A6H	NULL
to	NULL
induce	NULL
IL-2	NULL
production	NULL
.	NULL

Indeed	NULL
,	NULL
earlier	NULL
studies	NULL
show	NULL
an	NULL
increased	NULL
NF-kB	NULL
binding	NULL
activity	NULL
after	NULL
engagement	NULL
of	NULL
the	NULL
CD28	NULL
receptor	NULL
by	NULL
either	NULL
CD28	NULL
mAb	NULL
or	NULL
the	NULL
B7	NULL
native	NULL
ligand	NULL
suggesting	NULL
that	NULL
augmented	NULL
NF-xB	NULL
binding	NULL
activity	NULL
in	NULL
T	NULL
cells	NULL
is	NULL
a	NULL
hallmark	NULL
for	NULL
the	NULL
CD28	NULL
mediated	NULL
costimulatory	NULL
pathway.2*203°	NULL
CD8*	NULL
T	NULL
cells	NULL
costimulated	NULL
with	NULL
A6H	NULL
failed	NULL
to	NULL
respond	NULL
and	NULL
upregulate	NULL
the	NULL
activation	NULL
markers	NULL
IL-2R4	NULL
,	NULL
$	NULL
,	NULL
y	NULL
,	NULL
CD71	NULL
and	NULL
B7	NULL
,	NULL
to	NULL
produce	NULL
cytokines	NULL
and	NULL
proliferate	NULL
.	NULL

Furthermore	NULL
,	NULL
no	NULL
induction	NULL
of	NULL
AP-1	NULL
binding	NULL
protein	NULL
was	NULL
seen	NULL
in	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
costimulated	NULL
with	NULL
A6H	NULL
mAb	NULL
.	NULL

This	NULL
indicated	NULL
failure	NULL
of	NULL
the	NULL
A6H	NULL
pathway	NULL
to	NULL
induce	NULL
early	NULL
as	NULL
well	NULL
as	NULL
late	NULL
events	NULL
in	NULL
the	NULL
activation	NULL
cascade	NULL
in	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
inability	NULL
of	NULL
the	NULL
A6H	NULL
molecule	NULL
to	NULL
mount	NULL
a	NULL
costimulatory	NULL
response	NULL
in	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
may	NULL
reflect	NULL
structural	NULL
differences	NULL
in	NULL
the	NULL
A6H	NULL
molecule	NULL
in	NULL
CD8	NULL
*	NULL
compared	NULL
to	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
.	NULL

Alternatively	NULL
,	NULL
the	NULL
molecules	NULL
required	NULL
for	NULL
downstream	NULL
mobilization	NULL
of	NULL
AP-1	NULL
protein	NULL
are	NULL
active/present	NULL
in	NULL
CD4*	NULL
but	NULL
not	NULL
in	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
We	NULL
are	NULL
in	NULL
favour	NULL
of	NULL
the	NULL
latter	NULL
hypothesis	NULL
and	NULL
are	NULL
therefore	NULL
currently	NULL
investigating	NULL
the	NULL
pattern	NULL
of	NULL
protein	NULL
tyrosine	NULL
phosphorylation	NULL
induced	NULL
after	NULL
triggering	NULL
the	NULL
A6H	NULL
molecule	NULL
in	NULL
conjunction	NULL
with	NULL
anti-CD3	NULL
mAb	NULL
.	NULL

Indeed	NULL
,	NULL
a	NULL
number	NULL
of	NULL
specific	NULL
substrates	NULL
was	NULL
rapidly	NULL
tyrosine	NULL
phoshorylated	NULL
after	NULL
A6H	NULL
costimulation	NULL
in	NULL
CD3*	NULL
T	NULL
cells	NULL
,	NULL
including	NULL
proteins	NULL
of	NULL
148	NULL
000	NULL
,	NULL
70000	NULL
,	NULL
56000	NULL
,	NULL
46000	NULL
and	NULL
38	NULL
000	NULL
MW	NULL
,	NULL
data	NULL
not	NULL
shown	NULL
.	NULL

Nevertheless	NULL
,	NULL
it	NULL
remains	NULL
to	NULL
be	NULL
seen	NULL
whether	NULL
there	NULL
is	NULL
a	NULL
difference	NULL
in	NULL
the	NULL
pattern	NULL
of	NULL
tyrosine	NULL
phoshorylation	NULL
in	NULL
CD4+	NULL
-	NULL
compared	NULL
to	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
,	NULL
costimulated	NULL
with	NULL
the	NULL
A6H	NULL
mAb	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
We	NULL
thank	NULL
Drs	NULL
L.	NULL
Abrahamsén	NULL
and	NULL
G.	NULL
Forsberg	NULL
at	NULL
Pharmacia	NULL
&	NULL
Upjohn	NULL
Inc.	NULL
,	NULL
Stockholm	NULL
,	NULL
Sweden	NULL
for	NULL
assistance	NULL
in	NULL
the	NULL
production	NULL
of	NULL
recombinant	NULL
SEA	NULL
.	NULL

Dr	NULL
Robert	NULL
Vessella	NULL
,	NULL
University	NULL
of	NULL
Washington	NULL
,	NULL
Seattle	NULL
,	NULL
WA	NULL
and	NULL
Dr	NULL
David	NULL
Simmons	NULL
,	NULL
Oxford	NULL
,	NULL
UK	NULL
for	NULL
the	NULL
generous	NULL
gifts	NULL
of	NULL
the	NULL
mAbs	NULL
A6H	NULL
and	NULL
CD33Fc	NULL
,	NULL
respectively	NULL
.	NULL

Financial	NULL
support	NULL
was	NULL
obtained	NULL
from	NULL
the	NULL
Swedish	NULL
Cancer	NULL
Society	NULL
and	NULL
the	NULL
LEO	NULL
research	NULL
foundation	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Musirer	NULL
D.	NULL
L.	NULL
,	NULL
Jenkins	NULL
M.	NULL
K	NULL
&	NULL
ScHwartz	NULL
R.	NULL
(	NULL
1989	NULL
)	NULL
Clonal	NULL
expansion	NULL
vs.	NULL
clonal	NULL
inactivation	NULL
:	NULL
a	NULL
costimulatory	NULL
signalling	NULL
pathway	NULL
determines	NULL
the	NULL
outcome	NULL
of	NULL
T	NULL
cell	NULL
antigen	NULL
receptor	NULL
occupancy	NULL
.	NULL

Ann	NULL
Rev	NULL
Immunol	NULL
7	NULL
,	NULL
445	NULL
.	NULL

2	NULL
.	NULL

Jenkins	NULL
M.	NULL
K.	NULL
&	NULL
Jounson	NULL
J.	NULL
G.	NULL
(	NULL
1993	NULL
)	NULL
Molecules	NULL
involved	NULL
in	NULL
T	NULL
cell	NULL
costimulation	NULL
.	NULL

Curr	NULL
Opin	NULL
Immunol	NULL
5	NULL
,	NULL
361	NULL
.	NULL

3	NULL
.	NULL

JanEway	NULL
C.	NULL
A.	NULL
JR.	NULL
&	NULL
GoLpstEIN	NULL
P.	NULL
(	NULL
1993	NULL
)	NULL
Lymphocyte	NULL
activation	NULL
and	NULL
effector	NULL
functions	NULL
,	NULL
editorial	NULL
overview	NULL
:	NULL
the	NULL
role	NULL
of	NULL
cell	NULL
surface	NULL
molecules	NULL
.	NULL

Curr	NULL
Opin	NULL
Immunol	NULL
5	NULL
,	NULL
313	NULL
.	NULL

4	NULL
.	NULL

Rosey	NULL
E.	NULL
&	NULL
Aruson	NULL
J.P.	NULL
(	NULL
1995	NULL
)	NULL
T	NULL
cell	NULL
activation	NULL
:	NULL
integration	NULL
of	NULL
signals	NULL
from	NULL
the	NULL
antigen	NULL
receptor	NULL
and	NULL
costimulatory	NULL
molecules	NULL
.	NULL

Immunol	NULL
Today	NULL
16	NULL
,	NULL
307	NULL
.	NULL

5	NULL
.	NULL

Boussiortis	NULL
V.	NULL
A.	NULL
,	NULL
GRIBBEN	NULL
J.	NULL
G.	NULL
,	NULL
FREEMAN	NULL
G.	NULL
J	NULL
.	NULL

&	NULL
NapLeR	NULL
L.	NULL
M.	NULL
(	NULL
1994	NULL
)	NULL
Blockade	NULL
of	NULL
the	NULL
CD28	NULL
co-stimulatory	NULL
pathway	NULL
:	NULL
a	NULL
means	NULL
to	NULL
induce	NULL
tolerance	NULL
.	NULL

Curr	NULL
Opin	NULL
Immunol	NULL
6	NULL
,	NULL
797	NULL
.	NULL

6	NULL
.	NULL

Jenkins	NULL
M.	NULL
&	NULL
ScHwaRrTZ	NULL
R.	NULL
(	NULL
1987	NULL
)	NULL
Antigen	NULL
presentation	NULL
by	NULL
chemically	NULL
modified	NULL
splenocytes	NULL
induces	NULL
antigen	NULL
specific	NULL
T	NULL
cell	NULL
unresponsiveness	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
165	NULL
,	NULL
302	NULL
.	NULL

7	NULL
.	NULL

SpringER	NULL
T.	NULL
A	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Adhesion	NULL
receptors	NULL
of	NULL
the	NULL
immune	NULL
system	NULL
.	NULL

Nature	NULL
346	NULL
,	NULL
425	NULL
.	NULL

8	NULL
.	NULL

Van	NULL
Seventer	NULL
G.	NULL
A.	NULL
,	NULL
NewmwNn	NULL
W.	NULL
,	NULL
Suimizu	NULL
Y.	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Analysis	NULL
of	NULL
T	NULL
cell	NULL
stimulation	NULL
by	NULL
superantigen	NULL
plus	NULL
major	NULL
histoc-ompatibility	NULL
complex	NULL
class	NULL
II	NULL
molecules	NULL
or	NULL
by	NULL
CD3	NULL
monoclonal	NULL
antibody	NULL
:	NULL
costimulation	NULL
by	NULL
purified	NULL
adhesion	NULL
ligands	NULL
VCAM-1	NULL
,	NULL
ICAM-1	NULL
but	NULL
not	NULL
ELAM-1	NULL
.	NULL

Exp	NULL
Med	NULL
174	NULL
,	NULL
901	NULL
.	NULL

9	NULL
.	NULL

Fisuer	NULL
H.	NULL
,	NULL
A.	NULL
,	NULL
HEpLUuND	NULL
G.	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Stimulation	NULL
of	NULL
human	NULL
naive	NULL
and	NULL
memory	NULL
T	NULL
helper	NULL
cells	NULL
with	NULL
bacterial	NULL
super	NULL
antigen	NULL
.	NULL

Naive	NULL
CD4	NULL
+	NULL
45RA	NULL
+	NULL
T	NULL
cells	NULL
require	NULL
a	NULL
costimulatory	NULL
signal	NULL
mediated	NULL
through	NULL
the	NULL
LFA-1/ICAM-1	NULL
pathway	NULL
.	NULL

J	NULL
Immunol	NULL
148	NULL
(	NULL
1993	NULL
)	NULL
10	NULL
.	NULL

CLarK	NULL
E.	NULL
A	NULL
.	NULL

&	NULL
LepsettER	NULL
J	NULL
.	NULL

A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
How	NULL
B	NULL
and	NULL
T	NULL
cells	NULL
talk	NULL
to	NULL
each	NULL
other	NULL
.	NULL

Nature	NULL
367	NULL
,	NULL
425	NULL
.	NULL

11	NULL
.	NULL

Y.	NULL
,	NULL
van	NULL
SeveNTER	NULL
G.	NULL
A.	NULL
,	NULL
Horgan	NULL
K.	NULL
J	NULL
.	NULL

&	NULL
S.	NULL
(	NULL
1990	NULL
)	NULL
Roles	NULL
of	NULL
adhesion	NULL
molecules	NULL
in	NULL
Tcell	NULL
recognition	NULL
:	NULL
Fundamental	NULL
similarities	NULL
between	NULL
four	NULL
integrins	NULL
on	NULL
resting	NULL
human	NULL
T	NULL
cells	NULL
(	NULL
LFA-1	NULL
,	NULL
VLA-4	NULL
,	NULL
VLA-5	NULL
,	NULL
VLA-6	NULL
in	NULL
expression	NULL
,	NULL
binding	NULL
and	NULL
costimulation	NULL
.	NULL

Immunological	NULL
Rev	NULL
114	NULL
,	NULL
109	NULL
.	NULL

12	NULL
.	NULL

LaBupa	NULL
T.	NULL
,	NULL
Lanbo	NULL
P.	NULL
,	NULL
O.	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
A	NULL
novel	NULL
©1997	NULL
Blackwell	NULL
Science	NULL
Ltd	NULL
,	NULL
Immunology	NULL
,	NULL
90	NULL
,	NULL
236-243	NULL
20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

Costimulatory	NULL
effects	NULL
of	NULL
A6H	NULL
on	NULL
human	NULL
T	NULL
cells	NULL
co-stimulatory	NULL
T	NULL
cell	NULL
antigen	NULL
co-expressed	NULL
on	NULL
renal	NULL
cell	NULL
carcinoma	NULL
.	NULL

Int	NULL
Immunol	NULL
7	NULL
,	NULL
1425.	NULL
.	NULL

VEssELLA	NULL
R.	NULL
L.	NULL
,	NULL
Moon	NULL
T.D	NULL
.	NULL

,	NULL
CHOU	NULL
R.	NULL
K.	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1985	NULL
)	NULL
Monoclonal	NULL
antibodies	NULL
to	NULL
human	NULL
renal	NULL
cell	NULL
carcinoma	NULL
:	NULL
recognition	NULL
of	NULL
shared	NULL
and	NULL
restricted	NULL
tissue	NULL
antigens	NULL
.	NULL

Cancer	NULL
Research	NULL
45	NULL
,	NULL
6131.	NULL
.	NULL

Jain	NULL
J.	NULL
,	NULL
Lon	NULL
C.	NULL
&	NULL
Rao	NULL
A	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Transcriptional	NULL
regulation	NULL
of	NULL
the	NULL
IL-2	NULL
gene	NULL
.	NULL

Curr	NULL
Opin	NULL
Immunol	NULL
7	NULL
,	NULL
333.	NULL
.	NULL

NaBet	NULL
G.	NULL
&	NULL
Barrtimore	NULL
D.	NULL
(	NULL
1987	NULL
)	NULL
An	NULL
inducible	NULL
transcription	NULL
factor	NULL
activates	NULL
expression	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Nature	NULL
326	NULL
,	NULL
711.	NULL
.	NULL

GHos	NULL
P.	NULL
,	NULL
Tan	NULL
T.	NULL
H.	NULL
,	NULL
Rice	NULL
N.	NULL
R.	NULL
,	NULL
Sica	NULL
A	NULL
.	NULL

&	NULL
Young	NULL
H.	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
The	NULL
interleukin	NULL
2	NULL
CD28	NULL
responsive	NULL
complex	NULL
contains	NULL
at	NULL
least	NULL
three	NULL
members	NULL
of	NULL
the	NULL
NF-xB	NULL
family	NULL
:	NULL
c-rel	NULL
,	NULL
p50	NULL
and	NULL
p65	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
90	NULL
,	NULL
1696.	NULL
.	NULL

ULLMaAN	NULL
K.	NULL
S.	NULL
,	NULL
NortHROP	NULL
J.	NULL
P.	NULL
,	NULL
Apmon	NULL
A	NULL
.	NULL

&	NULL
CraBtrEE	NULL
G.	NULL
R.	NULL
(	NULL
1992	NULL
)	NULL
Jun	NULL
family	NULL
members	NULL
are	NULL
controlled	NULL
by	NULL
a	NULL
calcium-regulated	NULL
,	NULL
cyclosporin	NULL
A-sensitive	NULL
signalling	NULL
pathway	NULL
in	NULL
activated	NULL
T	NULL
lymphocytes	NULL
.	NULL

Genes	NULL
Dev	NULL
7	NULL
,	NULL
188.	NULL
.	NULL

Domsten	NULL
M.	NULL
,	NULL
HeprunNp	NULL
G.	NULL
,	NULL
AxerBLOM	NULL
E.	NULL
,	NULL
Lanpo	NULL
P.	NULL
A	NULL
.	NULL

&	NULL
KaLranp	NULL
T.	NULL
(	NULL
1991	NULL
)	NULL
Monoclonal	NULL
antibody-targeted	NULL
superantigens	NULL
:	NULL
a	NULL
different	NULL
class	NULL
of	NULL
anti-tumor	NULL
agents	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
88	NULL
,	NULL
9287.	NULL
.	NULL

Linstey	NULL
P.	NULL
S.	NULL
,	NULL
Brapy	NULL
W.	NULL
,	NULL
URnEs	NULL
M.	NULL
,	NULL
GROSMAIRE	NULL
L.	NULL
S	NULL
,	NULL
DamMLe	NULL
N.	NULL
K.	NULL
&	NULL
LepsETTER	NULL
J	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
CTLA-4	NULL
is	NULL
a	NULL
second	NULL
ligand	NULL
for	NULL
B	NULL
cell	NULL
activation	NULL
antigen	NULL
B7	NULL
.	NULL

J	NULL
exp	NULL
Med	NULL
174	NULL
,	NULL
561	NULL
.	NULL

ABraHAMsEN	NULL
L.	NULL
,	NULL
M.	NULL
,	NULL
Secren	NULL
S.	NULL
,	NULL
BJoRK	NULL
P.	NULL
,	NULL
Jonsson	NULL
E.	NULL
&	NULL
KaLtanp	NULL
T.	NULL
(	NULL
1995	NULL
)	NULL
Characterization	NULL
of	NULL
two	NULL
distinct	NULL
MHC	NULL
class	NULL
II	NULL
binding	NULL
sites	NULL
in	NULL
the	NULL
superantigen	NULL
staphyloccocal	NULL
enterotoxin	NULL
A.	NULL
EMBO	NULL
J	NULL
14	NULL
,	NULL
2978	NULL
.	NULL

WingREn	NULL
A.	NULL
G.	NULL
,	NULL
HEpLUND	NULL
G.	NULL
,	NULL
KaLtaND	NULL
T.	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
The	NULL
LFA-3	NULL
adhesion	NULL
pathway	NULL
is	NULL
differently	NULL
utilized	NULL
by	NULL
superantigen-activated	NULL
human	NULL
CD4	NULL
+	NULL
T-cell	NULL
subsets	NULL
.	NULL

Scand	NULL
J	NULL
Immunol	NULL
36	NULL
,	NULL
243	NULL
.	NULL

Carisson	NULL
R.	NULL
,	NULL
FiscHer	NULL
H.	NULL
&	NULL
S1doren	NULL
H.	NULL
O	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Binding	NULL
of	NULL
staphylococcal	NULL
enterotoxin	NULL
to	NULL
accessory	NULL
cells	NULL
is	NULL
a	NULL
requirement	NULL
for	NULL
its	NULL
ability	NULL
to	NULL
activate	NULL
human	NULL
T	NULL
cells	NULL
.	NULL

J	NULL
Immunol	NULL
140	NULL
,	NULL
2484	NULL
.	NULL

Lanbo	NULL
P.	NULL
A.	NULL
,	NULL
DouLstEn	NULL
M.	NULL
,	NULL
Hepuunp	NULL
G.	NULL
,	NULL
BrRODIN	NULL
T.	NULL
,	NULL
Sansom	NULL
D.	NULL
&	NULL
Karranp	NULL
T.	NULL
(	NULL
1993	NULL
)	NULL
Co-stimulation	NULL
with	NULL
B7	NULL
and	NULL
targeted	NULL
superantigen	NULL
is	NULL
required	NULL
for	NULL
MHC	NULL
class	NULL
II-independent	NULL
T-cell	NULL
proliferation	NULL
but	NULL
not	NULL
cytotoxicity	NULL
.	NULL

Immunology	NULL
80	NULL
,	NULL
236	NULL
.	NULL

ParRRA	NULL
E.	NULL
,	NULL
VarGa	NULL
M.	NULL
,	NULL
StGvarDsson	NULL
M.	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Costimulation	NULL
of	NULL
human	NULL
CD4	NULL
+	NULL
T	NULL
cells	NULL
with	NULL
LFA-3	NULL
and	NULL
B7	NULL
induce	NULL
distinct	NULL
©1997	NULL
Blackwell	NULL
Science	NULL
Ltd	NULL
,	NULL
Immunology	NULL
,	NULL
90	NULL
,	NULL
236-243	NULL
25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

243	NULL
effects	NULL
on	NULL
AP-1	NULL
and	NULL
NF-kB	NULL
transcription	NULL
factors	NULL
.	NULL

J	NULL
Immuno	NULL
!	NULL

155	NULL
,	NULL
1132	NULL
.	NULL

Maniatis	NULL
T.	NULL
,	NULL
Fritsch	NULL
E.	NULL
F	NULL
&	NULL
SamBROOK	NULL
S.	NULL
(	NULL
1982	NULL
)	NULL
In	NULL
:	NULL
Molecular	NULL
cloning	NULL
:	NULL
A	NULL
Laboratory	NULL
Manual	NULL
.	NULL

p.91	NULL
.	NULL

Cold	NULL
Spring	NULL
Harbor	NULL
Laboratories	NULL
,	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
,	NULL
NY	NULL
.	NULL

Romano	NULL
F.	NULL
M.	NULL
,	NULL
BisoGNnt	NULL
R.	NULL
,	NULL
LAMBERT	NULL
!	NULL

A.	NULL
er	NULL
al	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Regulation	NULL
of	NULL
NF-xB	NULL
nuclear	NULL
activity	NULL
in	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
:	NULL
role	NULL
of	NULL
CD28	NULL
antigen	NULL
.	NULL

Cell	NULL
Immunol	NULL
!	NULL

156	NULL
,	NULL
371	NULL
.	NULL

Rincon	NULL
M.	NULL
&	NULL
F.avELL	NULL
R.	NULL
A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
AP-1	NULL
transcriptional	NULL
activity	NULL
requires	NULL
both	NULL
T	NULL
cell	NULL
receptor-mediated	NULL
and	NULL
co-stimulatory	NULL
signals	NULL
in	NULL
primary	NULL
T	NULL
lymphocytes	NULL
.	NULL

EMBO	NULL
J	NULL
13	NULL
,	NULL
43726	NULL
.	NULL

Crort	NULL
M.	NULL
(	NULL
1994	NULL
)	NULL
Activation	NULL
of	NULL
naive	NULL
,	NULL
memory	NULL
and	NULL
effector	NULL
T	NULL
cells	NULL
.	NULL

Curr	NULL
Opin	NULL
Immunol	NULL
6	NULL
,	NULL
431	NULL
.	NULL

June	NULL
C.	NULL
H.	NULL
,	NULL
LepsetTTER	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
LinpsteN	NULL
T.	NULL
&	NULL
THomson	NULL
C.B	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Evidence	NULL
for	NULL
the	NULL
involvement	NULL
of	NULL
three	NULL
distinct	NULL
signals	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
IL-2	NULL
gene	NULL
expression	NULL
in	NULL
human	NULL
T	NULL
lymphocytes	NULL
.	NULL

J	NULL
Immunol	NULL
143	NULL
,	NULL
153	NULL
.	NULL

WINGREN	NULL
A.	NULL
G.	NULL
,	NULL
PARRA	NULL
E.	NULL
,	NULL
VARGA	NULL
M.	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
T	NULL
cell	NULL
activation	NULL
pathways	NULL
:	NULL
B7	NULL
,	NULL
LFA-3	NULL
and	NULL
ICAM-1	NULL
shape	NULL
unique	NULL
T	NULL
cell	NULL
profiles	NULL
.	NULL

Crit	NULL
Rev	NULL
Immunol	NULL
15	NULL
,	NULL
235	NULL
.	NULL

Duranp	NULL
D.	NULL
B.	NULL
,	NULL
Snaw	NULL
J.	NULL
P	NULL
,	NULL
Bush	NULL
M.	NULL
R.	NULL
,	NULL
ReptogE	NULL
R.	NULL
E.	NULL
,	NULL
BELAGaJF	NULL
R.	NULL
&	NULL
CraBTREE	NULL
G.R	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Characterization	NULL
of	NULL
antigen	NULL
receptor	NULL
response	NULL
elements	NULL
within	NULL
the	NULL
IL-2	NULL
enhancer	NULL
Mo/	NULL
Cell	NULL
Bio/	NULL
8	NULL
,	NULL
1715	NULL
.	NULL

ULLMAN	NULL
K.	NULL
S.	NULL
,	NULL
NortHrOP	NULL
J.	NULL
P.	NULL
,	NULL
Verweu	NULL
CL	NULL
.	NULL

&	NULL
CrastRreE	NULL
G.	NULL
(	NULL
1990	NULL
)	NULL
Transmission	NULL
of	NULL
signals	NULL
from	NULL
the	NULL
T	NULL
lymphocyte	NULL
surface	NULL
receptor	NULL
to	NULL
the	NULL
genes	NULL
responsible	NULL
for	NULL
cell	NULL
proliferation	NULL
and	NULL
immune	NULL
function	NULL
:	NULL
the	NULL
missing	NULL
link	NULL
.	NULL

Annu	NULL
Rev	NULL
Immunol	NULL
!	NULL

8	NULL
,	NULL
421	NULL
.	NULL

PipERNO	NULL
A.	NULL
G.	NULL
&	NULL
Notan	NULL
P.	NULL
(	NULL
1991	NULL
)	NULL
Nuclear	NULL
transcription	NULL
factors	NULL
that	NULL
bind	NULL
to	NULL
elements	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
:	NULL
induction	NULL
requirements	NULL
in	NULL
primary	NULL
human	NULL
T	NULL
cells	NULL
.	NULL

J	NULL
Immunol	NULL
!	NULL

147	NULL
,	NULL
2734	NULL
.	NULL

Jan	NULL
J.	NULL
,	NULL
VALGE-ArRCHER	NULL
V.	NULL
E.	NULL
&	NULL
Rao	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Analysis	NULL
of	NULL
the	NULL
AP-1	NULL
sites	NULL
in	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

J	NULL
Immunol	NULL
!	NULL

148	NULL
,	NULL
1240	NULL
.	NULL

RysEck	NULL
R.	NULL
P.	NULL
&	NULL
Bravo	NULL
R.	NULL
(	NULL
1991	NULL
)	NULL
C-Jun	NULL
,	NULL
Jun-B	NULL
and	NULL
Jun-D	NULL
differ	NULL
in	NULL
their	NULL
binding	NULL
affinities	NULL
to	NULL
AP-1	NULL
and	NULL
CRE	NULL
consensus	NULL
sequences	NULL
:	NULL
effect	NULL
of	NULL
Fos	NULL
proteins	NULL
.	NULL

Oncogene	NULL
6	NULL
,	NULL
533	NULL
.	NULL

Los	NULL
M.	NULL
,	NULL
Schenk	NULL
H.	NULL
,	NULL
Bauerte	NULL
P.	NULL
A	NULL
,	NULL
Droor	NULL
W.	NULL
&	NULL
OstHorr	NULL
K.	NULL
S.	NULL
(	NULL
1995	NULL
)	NULL
IL-2	NULL
gene	NULL
expression	NULL
and	NULL
NF-KB	NULL
activation	NULL
through	NULL
CD28	NULL
requires	NULL
reactive	NULL
oxygen	NULL
production	NULL
by	NULL
S5-lipoxygenase	NULL
.	NULL

EMBO	NULL
J	NULL
14	NULL
,	NULL
3731	NULL
.	NULL

Bing	NULL
S.	NULL
,	NULL
Jacinto	NULL
E.	NULL
,	NULL
His	NULL
:	NULL
M.	NULL
,	NULL
T.	NULL
,	NULL
Karin	NULL
M.	NULL
&	NULL
Ben-NERIAXH	NULL
Y	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
JNK	NULL
is	NULL
involved	NULL
in	NULL
signal	NULL
integration	NULL
during	NULL
costimulation	NULL
of	NULL
T	NULL
lymphocytes	NULL
.	NULL

Cell	NULL
.	NULL

77	NULL
,	NULL
727	NULL
.	NULL

